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II. ABSTRACT 
To ensure the integrity of an intensity modulated radiation therapy (IMRT) treatment, 
each plan must be validated through a measurement-based quality assurance (QA) 
procedure, known as patient specific IMRT QA.  Many methods of measurement and 
analysis have evolved for this QA.    There is not a standard among clinical institutions, and 
many devices and action levels are used.  Since the acceptance criteria determines if the 
dosimetric tools’ output passes the patient plan, it is important to see how these parameters 
influence the performance of the QA device.  While analyzing the results of IMRT QA, it is 
important to understand the variability in the measurements.  Due to the different form 
factors of the many QA methods, this reproducibility can be device dependent. 
These questions of patient-specific IMRT QA reproducibility and performance were 
investigated across five dosimeter systems: a helical diode array, radiographic film, ion 
chamber, diode array (AP field-by-field, AP composite, and rotational composite), and an 
in-house designed multiple ion chamber phantom. The reproducibility was gauged for each 
device by comparing the coefficients of variation (CV) across six patient plans.  The 
vii 
 
 
 
performance of each device was determined by comparing each one’s ability to accurately 
label a plan as acceptable or unacceptable compared to a gold standard.   
All methods demonstrated a CV of less than 4%.  Film proved to have the highest 
variability in QA measurement, likely due to the high level of user involvement in the 
readout and analysis.  This is further shown by how the setup contributed more variation 
than the readout and analysis for all of the methods, except film.  When evaluated for ability 
to correctly label acceptable and unacceptable plans, two distinct performance groups 
emerged with the helical diode array, AP composite diode array, film, and ion chamber in 
the better group; and the rotational composite and AP field-by-field diode array in the poorer 
group.  Additionally, optimal threshold cutoffs were determined for each of the dosimetry 
systems.  These findings, combined with practical considerations for factors such as labor 
and cost, can aid a clinic in its choice of an effective and safe patient-specific IMRT QA 
implementation.   
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VI. Chapter 1 
INTRODUCTION AND BACKGROUND 
1.1 Statement of the Problem 
 The advent of intensity modulated radiation therapy (IMRT) offers a highly 
conformal therapy with the ability to increase dose to the treatment site while reducing the 
toxicities associated with radiation therapy (Veldeman 2008).  Its use has seen an explosion 
of growth, with approximately 30% - 60% of cancer patients receiving IMRT treatment in 
the United States as of 2008 (Das 2008).  While there are dosimetric advantages to IMRT, 
this more complex technology uses intricate three dimensional dose distributions and a 
dynamic fluence delivery, requiring more rigorous quality assurance (QA) practices to 
ensure acceptable dose delivery and machine performance (Low 2011).   
The patient-specific validation of radiotherapy plans is an integral part of the clinical 
implementation of IMRT (Ezzell 2003).  Despite the importance of patient-specific QA, no 
standard has yet emerged, and implementation can vary among institutions (Nelms 2007).  
Many dosimeter approaches have been formulated to address this need, including but not 
limited to ion chamber, film, diode arrays, and ion chamber arrays (Low 2011).  In 
conjunction with this hardware, analysis techniques such as percent difference for point 
measurements and gamma analysis for planar measurements have emerged (Low 2003).  
These quantitative analyses also do not have a standard acceptance criteria threshold, and 
can vary by the institution (Nelms 2007).  Since studies in radiation therapy outcomes often 
compare treatments among many different radiation therapy departments, it is important to 
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establish dosimetric certainty to derive meaningful conclusions from these studies (Das 
2008).  Therefore, a deeper understanding of the patient-specific QA methods currently in 
use not only contributes to a safe and effective treatment of the patient, but also to progress 
in the field of radiation therapy as a whole. 
Given the myriad of implementations for patient-specific IMRT QA, this research 
endeavors to differentiate a selection of modalities, investigating the response of not only 
the mechanics of devices, but also the quantitative analyses applied to their outputs.  Since 
this project aims to reflect on the dosimetric systems in current clinical use, the following 
devices have been selected for investigation: a planar diode array (MapCheck, Sun Nuclear, 
Melbourne, Fl), a helical diode array (ArcCheck, Sun Nuclear, Melbourne, Fl) and a 
combination of a planar and point measurements using film (Kodak EDR2, Carestream, 
Rochester, NY) and Wellhofer cc04 ion chamber (CNMC, Nashville, TN).  Additionally, an 
ion chamber based dosimetric system made in-house will be used for further verification of 
the commercial devices.  The above devices’ differences or similarities in response to 
performing patient-specific IMRT QA will be investigated, along with the acceptance 
criteria used for deeming the IMRT plan acceptable for patient delivery. 
1.2 Background 
1.2.1 Intensity Modulated Radiation Therapy (IMRT) 
 Radiation treatments work under the principle of damaging the DNA of cancerous 
cells through ionizing radiation (Hall 2006).  A problem in this approach becomes 
immediately salient: how to damage the cancerous cells while minimizing the surrounding 
normal tissue damage?  This issue is more challenging in cases of close-lying critical 
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structures and organs at risk, such as in cancers of the head and neck.  The development of 
inverse planning was an enormous leap for the field of radiation therapy (Bortfeld 2006).  
Inverse planning allows the planner to input goals of target coverage and structure avoidance 
(Hartford 2009).  Subsequently, the software optimizes the fluence based on the input 
parameters, developing a plan where the beam can come from several angles and each beam 
position can contain modulated beamlets using a collimator such as the multileaf collimator 
(MLC), therefore sculpting the dose distribution within the patient (IAEA 2008).  The 
International Atomic Energy Agency defines IMRT as “a dose plan and treatment delivery 
that is optimized using inverse planning techniques for modulated beam delivery,” (IAEA 
2008).  With the power of inverse planning, the dose to the normal tissue can be reduced, 
allowing for complex plans with a potential escalation in dose to the tumor (Mell 2005).   
 The increased complexity of IMRT introduces new issues to be monitored.  These 
can include MLC accuracy, monitor unit (MU) delivery, beam modeling, and the accuracy 
of treatment planning algorithms (Ezzell 2003).  While the accuracy of 3-D plans can be 
confirmed with secondary calculation, IMRT plans are individually tested through direct 
delivery and measurement, thus performing an end-to-end evaluation of the plan’s safety 
and deliverability. 
 
1.2.2 Purpose and Description of Patient-Specific IMRT QA  
 The end-to-end test of an IMRT plan is known as Patient-Specific IMRT QA.  It 
treats a selected dosimeter/or dosimeter-phantom combination as if it was a patient.  The 
IMRT plan that is intended for the patient is copied within the treatment planning software 
(TPS) to a CT scan of the dosimeter and phantom.  The plan may be altered to accommodate 
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the QA technique being employed.  For example, all of the gantry angles may be changed to 
zero degrees to allow for only normal incidence to a diode array, or the MU may be scaled 
to appropriately expose a piece of film.  To test the plan transfer process, the new hybrid 
plan created for the dosimeter is transferred from the TPS to the record-and-verify system, 
just as a patient plan would be.  At the linear accelerator (linac), the dosimeter is set up 
according to the geometric needs of the measurement.  The plan is then loaded to the 
treatment console, and delivered to the dosimeter.  Measurements from this treatment are 
compared to what was expected from the TPS calculations using a set of pre-defined criteria.  
The quality assurance program has a set of passing and failing criteria that serve to provide a 
quantitative assessment of the patient plan.  If the plan passes this evaluation, it receives 
additional scrutiny from professionals such as physicians and physicists, before being 
ultimately delivered to the patient.  Patient-specific QA acts as a sentinel against errors 
which may emerge from any of the myriad steps in radiation therapy delivery.  Because it is 
an end-to-end process, every step of plan delivery is tested.  While the primary goal of 
patient-specific QA is to ensure that the plan can be administered as intended, it has the 
additional benefit of highlighting any repairs that may be required from the TPS end to the 
actual radiation delivery.  However, it may be difficult to pinpoint the exact cause of the 
error from a general patient-specific IMRT QA failure. Thus patient-specific QA not only 
helps to protect the safety and health of the patient, but also the functionality of the clinic. 
1.2.3 Theory of Measurement 
 Three dose measurement devices were investigated in this research: ion chamber, 
diode, and film.  An ion chamber functions by collecting ions produced in a cavity 
surrounded by a tissue-equivalent wall.  Because a point measurement is being made with a 
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finite collecting volume, an ion chamber can be susceptible to volume averaging effects.  
This can be a particular problem when the ion chamber is placed in high dose gradients or 
the volume is too large (Low 2011).  In this situation the ion chamber active volume collects 
charge from a region containing a potentially large range of doses, thus the ion chamber 
reading becomes an average dose, and may not accurately reflect the dose one intended on 
measuring.  An ion chamber provides many attractive features as a dosimeter.  It has very 
little directional dependence, exhibits fantastic stability, has minimal energy dependence, 
and can be traced to a calibration standard. 
 Diodes operate on the principle of p-n junctions.  The p region is doped to be an 
electron receptor, while the n region is doped to be an electron donor.  When placed 
together, a depleted region forms between the p-type and n-type region, creating an electric 
field in an equilibrium state.  This depleted region functions as the active region of the 
diode, with radiation creating electron-hole pairs leading to a radiation-induced current 
which is measured.  Diodes are about 18,000 times more sensitive than an ion chamber 
because the ionization energy is less in silicon than in air, and can have much smaller active 
volumes than an ion chamber (Khan 2010).  However, diodes can suffer from an energy 
dependent response due to their higher atomic number.  They also have a directional 
dependence with sensitivity variation up to 3% when irradiated perpendicular to the diode 
axis (Low 2011). 
 Radiographic film consists of a clear film base coated in an emulsion containing a 
small amount of silver bromide.  When irradiated and then developed, the silver bromide 
crystals that were exposed are reduced to metallic silver, leaving a darkened latent image on 
the film.  The non-irradiated areas are left more transparent.  Radiographic film has 
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excellent spatial resolution due to the small grain size in the emulsion coating.  However, the 
silver increases the effective Z of the film, making it more sensitive to lower energy 
radiation and scatter.  Measurements with film are also dependent on the processor 
conditions and film batch (Low 2011). 
1.2.4 Theory of Quantitative Analysis 
 When using a planar measurement in patient-specific IMRT QA, the gamma analysis 
(Low 1998) is often used.  This method combines the concepts of dose difference and 
distance to agreement to compare a measured plane with a computed expected dose.  Dose 
difference is expressed as a percent difference between two matching points in the measured 
and calculated distributions.  It is particularly useful in regions of low dose gradient.  In high 
dose gradient regions, if the planes are displaced by a small amount, a large percent 
difference will result which is not representative of how well the planes match.  Therefore, 
in a high dose gradient, the distance from a point on one plane to the closest matching dose 
in the reference plane is a more appropriate metric.  To incorporate these two concepts, a 
horizontal plane representing the spatial distance from the measured point to the 
corresponding calculated point (|rc – rm|) is combined with a vertical plane representing the 
difference in dose between the measured and calculated points Dc(rc) – Dm(rm).  A line is 
drawn in this three dimensional space connecting the measured point and its corresponding 
calculated point.  The value of this line is Γ(rm, rc), given by the equation 
 
         
   
   
         
   
      Equation 1 
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Where r is the spatial distance to agreement |rc – rm|, δ is the dose difference Dc(rc) – Dm(rm), 
ΔdM is the distance to agreement criteria (e.g. 3mm), and ΔDM is the dose difference criteria 
(e.g. 3%).  In computing the gamma index value, the calculated point is taken as the point 
that minimizes Γ.  This minimized Γ is expressed as γ(rm).  When γ is less than or equal to 
one, then the calculation at that point passes, otherwise it fails.  This process is repeated for 
all the points in the planar measurement, yielding many points labeled either passing or 
failing.  The percent of pixels passing is a summary metric allowing the evaluator to 
quantify the percentage of the calculated points which passed the gamma analysis. 
 For point measurements, as with the ion chamber, a simple percent difference 
between what was measured and what was expected from the treatment planning system is 
used.  A threshold of percent difference is used to discriminate between failing and passing 
point measurements.  
1.3 Hypothesis and Specific Aims 
 In order to ensure the integrity of an intensity modulated radiation therapy (IMRT) 
patient treatment plan, each plan must be validated through a quality assurance (QA) 
procedure.  Since an IMRT treatment is a complex three-dimensional composition of many 
beams, hand calculations are inadequate, and measurements must be taken (Wilcox 2008).  
Many methods of measurement and analysis have evolved for patient specific IMRT QA.  
There is not a standard among clinical institutions, and many devices (such as ion chambers, 
diodes, and film) and many action levels are used (Nelms 2007).  According to the AAPM 
Task Group Report 120 (Low 2011), each detector for IMRT comes with its own advantages 
and disadvantages.  Because the accuracy of the patient’s treatment is dependent on these 
8 
 
 
 
measurement techniques, it is important to know how these different tools compare in 
performance.  Kruse (Kruse 2010) took measurements of the same plans using an ion 
chamber array and EPID.  From his data, differences in the fraction of pixels passing can be 
noted across the modalities.  However, this paper only investigates two dosimetric tools, 
while many more exist and are used clinically.  Along with every measurement, action 
levels must be established to evaluate if the plan is passing or failing.  Different institutions 
apply different acceptance thresholds, with 3%/3mm being the most common (Nelms 2007). 
Since the acceptance criteria determines if the dosimetric tools’ output passes the patient 
plan, it is important to see how these parameters influence the performance of the QA 
device.  While analyzing the results of IMRT QA, it is important to understand the natural 
variability in the measurements.  This variability could result from set-up and the machine’s 
delivery.  Due to the different form factors of the many QA methods, this reproducibility 
could be device dependent. 
Hypothesis 
 
The sensitivity among five patient specific IMRT QA detectors using clinically relevant 
action limits of 3%/3mm and 90% of pixels passing for planar, and 3% dose difference for 
point measurements to detect failing plans will not exceed 0.90 when compared to a multiple 
ion chamber phantom standard. 
 
 
  
9 
 
 
 
Specific Aims 
The following specific aims will assess this hypothesis: 
 
1.  To determine the reproducibility in the set up and delivery of IMRT plans to the 
ArcCheck, MapCheck, Multi Ion Chamber Phantom, EDR2 Film, and cc04 Ion 
Chamber 
 
2.  To measure and compare the passing rates of the ArcCheck, Mapcheck, ion 
chamber, and film for a series of IMRT patient plans, using the Multi Ion Chamber 
Phantom as a gold standard. 
 
1.4 Overview of Thesis Structure 
 This thesis serves to address the central hypothesis through pursuing the two specific 
aims given above.  Chapters three and four are self contained studies which address specific 
aims one and two, respectively.  Each includes its own introduction, methods, results, 
discussion, and conclusion sections that address the goals of each specific aim.   
 Chapter two is an overarching methods section that more rigorously describes the 
steps taken in the measurement and analysis of this research.  This includes a thorough 
discussion of some of the statistical methods employed in the data analysis.  Because 
receiver operator characteristic (ROC) curve analysis was such a large part of specific aim 
two, APPENDIX I will separately discuss this aspect. 
 Chapter five summarizes this thesis work as a whole, discussing and providing 
conclusions that have been drawn from all of the specific aims.  Also, suggestions for future 
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work are explored.  While a selection of relevant figures and data are printed within chapters 
three and four, a more complete set of data is provided in APPENDIX IV for the reader’s 
reference. 
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VII. Chapter 2 
THEORY OF METHODS 
2.1 Patient Selection 
In order to test a suite of IMRT patient-specific QA devices, as well as some of the 
various methods in which they are employed, a set of IMRT patient plans were selected.  In 
order to fully test the abilities of each IMRT QA system, it was important to incorporate a 
variety of plans of different sites and challenge levels.  To satisfy this first desire, plans were 
chosen from a variety of treatment sites: genitourinary, head and neck, gynecological, 
mesothelioma, gastrointestinal, Mantle, Lung, Spine, and Stereotactic treatments.  For the 
second goal, twenty plans that had previously failed film and ion chamber QA were chosen 
from the database of previous IMRT QA at the author’s institution.  Additionally five plans 
were also selected from this same database that had previously passed QA.  Since the results 
of this project aim to be as clinically relevant as possible, it was decided to use only actual 
plans that were utilized in the clinic.  Other studies that have investigated the performance of 
IMRT QA devices have generated failing plans by deliberately perturbing some part of the 
plan, such as MLC alignment.  In this project, by using only clinical plans that underwent 
QA the author endeavors to capture only the challenges that are realistically encountered, 
thus providing a more readily applicable assessment of the capabilities of the devices and 
methods under discussion. 
 The 25 plans that were selected were all recalculated in the treatment planning 
software (TPS) Pinnacle
3
 Version 9 (Philips Medical Systems, Andover, MA).  The ion 
chamber measurements from the original IMRT QA of the 25 plans were compared to the 
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mean ion chamber dose that was recalculated in Pinnacle
3
 Version 9.  This ensured that 
these plans had failed QA by greater than plus or minus 3% according to the most current 
abilities of dose calculation.  Having this additional test helps to select for plans that are 
challenging and not simply failures due to calculation errors from weaknesses in older 
versions of a TPS.  Furthermore, all plans were calculated in Pinnacle
3
 Version 9 when they 
were copied to the various phantoms being investigated. 
 These plans were required to be delivered on a variety of dosimeters.  One of the 
previously failing plans (a lung stereotactic case) proved to have too small of a field to be 
adequately measured by all of the detector systems being studied.  Therefore, this patient 
plan was excluded from the analysis, leading to a total of 24 patient plans in this study. 
2.2 Dosimeters Studied 
 This work analyzed the performance of several dosimetric systems, necessitating a 
familiarization with a variety of software and analyses.  Chapter 3 and Chapter 4 describe an 
overview of how these systems were used, but we present here a more thorough discussion 
of the methods employed. 
2.2.1 Diode Array 
 A diode array dosimetry system containing 1527 diodes with a custom phantom 
(MapCheck2 with MapPhan, Sun Nuclear Corporation, Melbourne, FL) was the first IMRT 
QA device to be studied.  Measurements were taken in the form of absolute dose. In order to 
do this, a dose calibration was performed within the accompanying SNC Patient software.  
Before every measurement session, an output check was performed (according to the 
procedures of monthly QA) so that the absolute dose calibration would incorporate any daily 
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fluctuations in output.  The output fluctuated by less than 1% across all measurement 
sessions.  Additionally, an array calibration was performed at the beginning of the first 
measurement session to correct for any non-uniform response from the diodes. 
 All diode array measurements were taken with the MapCheck inside the MapPhan, 
providing 5cm of water equivalent buildup and backscatter along the coronal and sagittal 
sides of the array (Figure 1).  The manufacturer discusses in its product documentation that 
this setup would allow for measurements to be taken from non-normal incidence beams 
(SunNuclear 2010).   
 
Figure 1 Irradiation setup for MapCheck placed within MapPhan phantom 
During rotational deliveries, care was taken to avoid irradiating through the couch 
rails.  Therefore for each field, if the beam angle was between 160 – 205 degrees, both rails 
were moved to their most lateral extent; if the angle was either between 115 – 135 or 225 – 
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245 degrees, both rails were positioned in their most medial extent (Pulliam 2011).  This 
procedure was followed for all dosimeters which made measurements from plans delivered 
with original gantry angles. 
Two setup geometries were explored for the MapCheck: one in which all beams 
were delivered perpendicular to the array, and one in which the beams were delivered with 
their original gantry angles (i.e., rotational delivery).  Both types of measurements recorded 
each field individually.  For the rotational deliveries, all array measurements from each 
beam were summed into a composite planar measurement for comparison with the fluence 
plane output from the TPS.  The plans that were delivered with all beams anterior-posterior 
(AP) were subdivided into two separate analysis groups: one in which all of the AP fields 
were summed together into a composite as with the rotational deliveries, and one in which 
each field was left separate for a field-by-field analysis.  Since the final gamma analysis was 
performed in both SNC Patient and DoselabPro (Mobius Medical Systems, Houston, TX), 
the composite plans were formed from the raw data in both systems.  The output in SNC 
Patient was a text file similar in format to the original raw measurements.  The output from 
DoselabPro was a tiff file.   
Gamma analysis was performed to obtain the percent of pixels passing for each 
MapCheck measurement for all three methods of measurement (AP, AP composite, and 
rotational).  The gamma analysis was performed in both SNC Patient and Doselab Pro 
(although in the reproducibility study, only the DoselabPro results were considered).  In 
SNC Patient, a dose threshold of 10% was used with distance to agreement (DTA) and dose 
difference (DD) criteria set to 2%/2mm, 3%/3mm, and 5%/3mm.  The analysis was 
performed in absolute dose mode, and batch analysis was used to make the process more 
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efficient.  In DoselabPro, no normalization was used.  In order to minimize the human 
dependence on ROI selection, auto-ROI was used.  In Doselab, the auto ROI algorithm 
creates a box bounding the region of the plane containing greater than 30% of the maximum 
dose.  Then a boundary of 10% of the width and height are added to all sides to create the 
final ROI.  Because the geometry of the diode array is not rectangular, in order to guarantee 
that the rectangular ROI DoselabPro uses would not select regions of the plane lacking 
diode measurements (Figure 2), a Matlab (MathWorks, Natick, MA) script was written. This 
script overwrote the reference plan exported from the TPS with zeros in regions where there 
not any corresponding diodes in the measurement plane.  In this way, any discrepancies 
between the two planes would be due to dosimetric differences, not detector geometry.  
Auto-registration of the two planes was performed, and then manually fine tuned to provide 
the most accurate alignment.  Additionally, no dose threshold was used for gamma analysis 
in Doselab, since the software uses relative percent difference instead of local percent 
difference. 
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Figure 2 When the detector geometry did not match the TPS exported plane geometry, 
errors in the gamma analysis could result from a large ROI. These regions were 
therefore excluded with an in-house script. 
 
Since planes for each beam of the field-by-field analysis had to be exported from 
Pinnacle, a script was written to facilitate this.  Pinnacle does not allow the user to directly 
export fluence planes of individual beams without normalizing each beam by its associated 
17 
 
 
 
number of monitor units (MU).  To overcome this limitation, a script was written that zeros 
the MU for all beams except the one being exported.  Now the “composite” exported plane 
will only contain information from the beam in question, and it will not be normalized by 
the MU.  This was cycled through each beam of each patient plan to generate a reference 
plane of absolute dose for each field. 
2.2.2 Radiographic Film and Ion Chamber 
 The next QA dosimeter system investigated was the EDR2 film (Kodak Carestream, 
Rochester, NY) and Wellhofer cc04 ion chamber (CNMC, Nashville, TN) combination in 
the I’mRT body phantom (IBA dosimetry, Schwarzenbruck, Germany) (Figure 3).  Since 
film and ion chamber have different measurement geometries and analysis techniques, each 
one’s performance was considered separately in this work.  
 
Figure 3 The irradiation setup for the film and ion chamber dosimeters 
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 The ion chamber used has a volume of 0.04cc, an inner diameter of 4.0mm, an active 
length of 3.6mm, and an electrode with a 1mm diameter (CNMC 2009).  The film has a 
responsive range of 24 – 400cGy, with an approximate saturation exposure of 700cGy 
(Kodak 2001).  Its dimensions are 10 x 12 inches.  The ion chamber measurements were 
made with a Model 206 electrometer (CNMC, Nashville, TN).  10 cm x10 cm fields 
delivered 200MU at 90 and 270 degrees to create a transfer factor converting the ion 
chamber charge measurements to dose, while incorporating daily fluctuations in output and 
environment. At the end of a plan delivery, the total accumulated dose was compared to the 
average dose calculated to the ion chamber ROI in the TPS.  Percent difference was 
calculated by: 
  
                           
              
    Equation 2 
EDR2 radiographic film contains less silver than other radiographic film, leading to 
minimal over-response to low energy radiation (Childress 2005).  An eight field calibration 
was delivered for each batch of film to create a sensitometric curve to account for variations 
in response from batch to batch.  The film was positioned parallel to the beams during plan 
delivery.  Holes were poked into the film while it was still in the phantom after delivery in 
order to provide marks for geometrical registration, as well as remove potential air gaps.  All 
of the films were developed between one and two days post irradiation.  The films were 
scanned on a VIDAR VXR-16 Dosimetry Pro (VIDAR Systems Corporation, Herndon, 
VA), at a resolution of 71dpi.  The gamma analysis was performed in the Omnipro I’mRT 
software (IBA Dosimetry, Schwarzenbruck, Germany) at 2%/2mm, 3%/3mm, and 5%/3mm, 
with a 10% dose threshold.  Figure 4 shows a screenshot of what this analysis looked like.  
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The reference dose was the calculated dose, while the film was the evaluated distribution.  
The film scan was initially normalized to the maximum dose in the calculated plane, and 
then manual optimization of the normalization point was performed.  The resulting percent 
of pixels passing the DTA and DD criteria were recorded. 
 
Figure 4 A screenshot of the gamma analysis for film performed in OmniPro I’mRT 
software 
 
2.2.3 Helical Diode Array   
The cylindrical diode array (ArcCheck, Sun Nuclear Corporation, Melbourne, FL) 
was developed to have a form factor that is more conducive to measurements performed 
under rotational delivery (Figure 5).  The 1386 diodes are placed in a helical pattern to 
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reduce the amount of detector overlap, and to obtain a more three dimensional view of the 
measured dose distribution as compared to a 2D array measurement.  Measurements were 
taken with the accompanying SNC Patient software.  As with the MapCheck2 array, dose 
calibrations were performed to account for a non-uniform diode response and daily 
fluctuations when converting the measured fluence to dose.  Gamma analysis was performed 
in the SNC Patient software with gamma criteria of 2%/2mm, 3%/3mm, and 5%/3mm with 
a dose threshold of 10%.  The percent of pixels passing were recorded. 
 
Figure 5 Irradiation setup for the ArcCheck QA dosimetry device. 
2.2.4 Multiple Ion Chamber Phantom 
 A non-commercial dosimeter was also used in this research (Figure 6).  The in-house 
designed multiple ion chamber phantom (MIC) contains 5 five Exradin A1SL 0.057cc ion 
chambers at 3-dimensionally independent locations.  The dose to each ion chamber was 
calculated with the formula 
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 .   Equation 3 
The    
     term was obtained from the ADCL calibration on all five ion chambers.  KQ, Pion, 
and Ppol were estimated from the work by McEwen (McEwen 2010).  During the beginning 
of every session, a 20 cm x20 cm field (so as to not place any of the ion chambers in the 
penumbra) of 100MU was delivered to the MIC to account for fluctuations in daily output.  
Temperature and pressure were also measured to correct for environmental changes. 
 
Figure 6 Irradiation setup for the Multiple Ion Chamber Phantom 
2.3 Data Analysis 
In order to address specific aim one, an analysis of reproducibility was pursued.  To 
accomplish this, the coefficient of variation (CV) was used as the metric of reproducibility. 
It is defined as 
                         
                  
         Equation 4 
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Because the coefficient of variance is normalized by the mean, this makes it more robust to 
comparing samples with inherently different values, since samples with a higher average 
mean will tend to have a higher standard deviation (Rosner 2011).  We were interested in 
seeing if there was a way to place these QA devices into statistically significant groups 
based on their CV.  First an analysis of variance (ANOVA) was performed to see if the 
underlying mean CV calculated across different patient plans for each QA device was the 
same.  This test compares the variability resulting from between groups and within groups.  
Once it was determined that at least two of the device group means were not the same from 
the ANOVA test, a post-hoc Tukey Honestly Significant Difference (HSD) test was done to 
see which groups differed.  The test is performed by comparing the absolute difference in 
the means of each group to the value of HSD.  HSD is defined as 
 
                            
                               
  
                                                              Equation 5 
If the absolute difference in the means of two groups is greater than the HSD value, then the 
two groups are considered statistically different (Abdi 2010). 
 In pursuing the research for specific aim one, the opportunity was seen to compare 
the reproducibility of an ion chamber measurement to the standard deviation in the 
calculated dose across the ion chamber volume.  To see how these two concepts compare, a 
regression analysis was used to gauge how well the knowledge of the calculated standard 
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deviation in dose across the ion chamber ROI could predict the reproducibility of the 
measurement.  To account for the uncertainty of the fitted line (i.e. if the experiment was 
repeated, how the relationship between these two variables might change), confidence 
intervals were calculated.  However, these confidence intervals give information about dose 
standard deviation predicting the expected, mean value of standard deviation in the 
measurement.  To demonstrate the confidence in predicting the actual values of 
measurement standard deviation, a wider prediction interval was also calculated to 
encapsulate the expected values with the error from that observation (Ruppert 2003).   
 Since this regression analysis took data from five different Exradin A1SL ion 
chambers making measurements on six different patient plans, the effects of the choice in 
ion chamber or plan were investigated via looking at the autocorrelation of residuals (for 
plots of the autocorrelation see the additional figures of APPENDIX IV).  Since no effect 
was found from choice of plan or ion chamber, the regression analysis could be pursued 
with confidence knowing that these errors were uncorrelated. 
 For specific aim two, a Receiver Operating Characteristic (ROC) analysis was used.  
Details of this type of analysis and how it was applied to this body of research is given in  
APPENDIX I.  When the ability of each device to detect acceptable and unacceptable plans 
was compared, an ANOVA with a post hoc Tukey HSD test was performed, as in specific 
aim one.  This allowed us to see which devices were significantly different in terms of their 
performance. 
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VIII. Chapter 3 
REPRODUCIBILITY IN PATIENT-SPECIFIC IMRT QA 
8.1 Introduction 
 Intensity modulated radiation therapy (IMRT) has become ubiquitous in radiation 
therapy clinics.  The increased complexity of IMRT plans necessitates a quality assurance 
(QA) approach that departs from the traditional hand calculation-based verification.  IMRT 
plans are clinically validated using direct measurement for each patient.  To satisfy this 
need, a number of devices have been developed to measure doses from the IMRT patient 
plan, which is then compared to the intended dose distribution calculated by the treatment 
planning system (TPS). 
 For the sake of convenience, several metrics have been adopted that allow for the 
sorting of plans as passing or failing, where a passing plan indicates that the delivered dose 
distribution adequately reflects the intended dose distribution (as calculated by the TPS).  
Two of these metrics are percent difference and percent of pixels passing the gamma 
criterion (Low 1998).  Percent difference is often used with point measurements, such as 
with an ion chamber, while the gamma analysis is used for planar measurements such as 
film or a diode array.  The institution chooses a threshold value for these metrics to indicate 
whether the plan might or might not be suitable to be delivered to a patient.  However, the 
credibility of this sorting rests in part on the reproducibility of the sorting; the 
reproducibility of the sorting resting in turn on the reproducibility in the delivery of the plan 
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and the dose measurements. A robust IMRT QA system therefore requires good 
reproducibility of the measured dose. 
 Previous studies in the literature have explored the reproducibility of individual 
measurements. For example, Mancuso et al looked at the reproducibility of ion chamber, 
film, and 2D diode array measurements in patient specific IMRT QA (Mancuso 2012).  
However, this work looked at the structure set geometries given in TG119 (Ezzell 2009). 
Fraser et al. (Fraser 2009) investigated the reproducibility of different ion chambers for 
IMRT QA. However, no prior study, to the author’s knowledge, has explored the 
reproducibility of IMRT QA results on clinical IMRT plans compared across a wide array of 
devices. This paper therefore explores the variation in the measured dose for several IMRT 
QA devices subjected to repeat measurements and analysis. 
8.2 Methods and Materials 
3.2.1 Plans 
Six different step-and-shoot IMRT patient plans which had previously undergone 
patient-specific IMRT QA were selected from the authors’ institution database.  To select 
for varying degrees of complexity three of the plans were chosen from a pool of plans that 
previously failed our internal film and ion chamber based QA (Dong 2003), and three of the 
plans were previously passing.  Additionally, different treatment sites were selected: one 
from thoracic, one from head and neck, one from gynecological, another two from thoracic, 
and one from gastrointestinal. Henceforth, these six plans will be referred to as THOR1, 
HN1, GYN1, THOR2, THOR3, and GI1, with the first three coming from the failing pool 
and the last three coming from the passing pool.  All plans were calculated in Pinnacle
3
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version 9 (Philips Medical Systems, Andover, MA), and all plans were developed with the 
same TPS beam model with exclusively 6MV photons.   
3.2.2 Delivery Methods 
All plans were delivered on accelerators with matched Varian 21EX beam models 
(Varian Medical Systems, Palo Alto, CA).  For any given dosimeter, all measurements were 
taken exclusively on the same linear accelerator within a single evening. 
Five clinical dosimeters and one in-house designed dosimeter were utilized for this 
study: EDR2 film ((Kodak Carestream, Rochester, NY)), Wellhofer cc04 ion chamber 
(CNMC, Nashville, TN), MapCheck2 in the MapPhan phantom (Sun Nuclear Corporation, 
Melbourne, FL), ArcCheck (Sun Nuclear Corporation, Melbourne, FL), and a multiple ion 
chamber (MIC) phantom. 
For each dosimeter, after an initial setup, each plan was delivered three times.  The system 
was then perturbed, re-setup, and re-irradiated (for a fourth time).  The system was perturbed 
again, re-setup again, and re-irradiated again (for a fifth time).  Ultimately, this yielded three 
irradiations delivered under a single setup (“redelivery”), and three irradiations under an 
independent setup (“total delivery”) for each patient plan on every device, with the third 
irradiation from the “redelivery” measurements being counted as one of the independent 
setups for the “total delivery” measurements.  The “redelivery” measurements were 
performed to assess the reproducibility of the machine delivery and device readout, as well 
as the analysis associated with that QA dosimeter.  The “total delivery” measurements 
incorporate both the variability seen in the “redelivery” measurements, as well as variability 
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introduced from the setup of the equipment.  A flow chart below offers a visual 
representation of this workflow [Figure 7]. 
 
Figure 7 The workflow used to generate measurements for “total” and “redelivery” 
reproducibility.  This same workflow was performed on all six patient plans on all 
IMRT QA devices studied 
 
3.2.3 Dosimeters Used 
The EDR2 film and cc04 ion chamber were placed in an I’mRT body phantom (IBA 
Dosimetry, Schwarzenbruck, Germany), with the film placed in the transverse plane.  The 
phantom was shifted to allow the ion chamber to have an average dose of at least 70% of the 
maximum dose in the plan, and a standard deviation equal to or less than 1% of the mean 
value dose across the active volume of the ion chamber, in accordance with the practices 
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performed at the author’s institution.  This procedure is done with the goal of placing the ion 
chamber in a high dose, low gradient region.  All plans were delivered with their original 
gantry angles. 
Because radiographic film and an ion chamber make fundamentally different 
measurements with differing geometries, these two dosimeters were considered separately in 
assessing their reproducibility.  For the film, a gamma analysis in OmniPro I’mRT (IBA 
Dosimetry, Schwarzenbruck, Germany) with a 10% dose threshold and criteria of 3%/3mm 
was used for the reproducibility analysis. 
The MapCheck2 diode array was placed within 5 cm of water equivalent buildup and 
5cm for backscatter. The device was then irradiated and analyzed in 3 different 
configurations. First, it was delivered with gantry angles set to zero degrees for an AP beam 
delivery.  This was further broken down into a (1) field-by-field gamma analysis, and a (2) 
composite AP analysis. Thirdly, the (3) original gantry rotational gantry angles from the 
IMRT plan were delivered to the MapCheck in the MapPhan phantom.  Per the 
manufacturer’s instructions, if the majority of angles for any plan came from near 90 or 270 
degrees the array would have been placed sagittally.  However, since this was not the case 
for any of the plans under investigation (none had a majority of beams coming from either 
70-100 degrees or 250-290 degrees), all plans were delivered with the MapCheck flat on the 
treatment couch. This measurement was followed with a gamma analysis on the rotational 
composite field.  For all three conditions, all gamma analysis was done at 3%/3mm in the 
DoseLab Pro software (Mobius Medical Systems, Houston, TX), with an automatically 
selected ROI and using absolute dose.  The measured plane was the reference distribution in 
the gamma analysis. 
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 The ArcCheck was positioned on the couch, with shifts away from or towards the 
gantry as was necessary to avoid irradiation of the electronics, and to center the treatment 
plan on the center diodes.  Gamma analysis was performed in the SNC Patient software (Sun 
Nuclear Corporation, Melbourne, FL) at 3%/3mm, with an ROI that encompassed all of the 
diodes, using absolute dose mode, and using the measured plane as the reference distribution 
in the gamma analysis.  
The in-house designed multiple ion chamber phantom (MIC) consisted of five 
Exradin A1SL 0.57cc ion chambers set at three-dimensionally independent points (different 
depths, heights, and lateral positions).  The holes for the ion chambers were set in an insert 
that can rotate to eight different positions.  This allowed for the flexibility to position the ion 
chambers such that the number of ion chambers in a high dose, low gradient region was 
maximized.  This gave five ion chamber measurements per irradiation.  Each ion chamber 
was completely independent, having its own tri-axial cable and electrometer.  The measured 
dose from each ion chamber was used in the reproducibility analysis.  The coefficient of 
variance was calculated for each of the five ion chambers, and then averaged over each 
patient plan to arrive at a summary statistic. 
3.2.4 Methods of Analysis 
In order to evaluate the reproducibility, the data was divided into “redelivery” and 
“total delivery” conditions as defined under Delivery Methods above.  The three 
measurements for the “redelivery” and “total delivery” groups were evaluated together to 
find the standard deviations and coefficients of variation.  Ultimately, this yields a 
coefficient of variation for each patient on each IMRT QA method for both types of 
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reproducibility (“redelivery” and “total delivery”).  The “total delivery” measurement 
captures the variation introduced by the delivery/readout and the setup, added in quadrature 
on the reasonable assumption that these errors are uncorrelated because they relate to 
independent processes.  Also these measurements are estimates of the underlying standard 
deviation in the population, therefore we can use them to solve for an estimate of the 
population standard deviation in the setup. 
Equation 6 
                        
         
                               
Therefore, reproducibility in the setup can be extracted from the “total delivery” 
measurement by removing the “redelivery” measurement component.  This allows us to 
explore how much variability is derived from the setup and how much from the 
delivery/readout.           
 Follow-up analysis for point dosimetry was conducted as related to the 
reproducibility in a measurement.  Ion chambers are accepted as a trusted standard in the 
field of dosimetry (Low 2011), however in patient specific IMRT QA the ion chamber is 
often utilized outside of reference conditions (Fraser 2009).  There is an assumption that 
minimizing the gradient across the ion chamber and placing the ion chamber in a high dose 
region is related to a more reproducible measurement. A common method of determining if 
the chamber is in an acceptable gradient is by looking at the standard deviation of the dose 
across the ion chamber volume as calculated by the TPS.  By comparing the standard 
deviation in the dose across the ion chamber active volume with the measured standard 
deviation in repeated measurements, this work analyzes that assumed relationship. This was 
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done by plotting the standard deviations of the dose to the ion chamber ROI as calculated in 
Pinnacle
3
 9.0, versus the standard deviations found in the measurements.  The R statistical 
package was used to perform a regression analysis. A minimum dose threshold based on a 
percentage of the maximum dose in the plan is an additional criteria used to select an 
appropriate ion chamber measurement point.  This method is used to place the ion chamber 
in an adequately high dose region.  A similar regression analysis comparing the standard 
deviation in the measurement to the percent of the plan maximum dose was performed to 
analyze this relationship. 
 
8.3 Results 
Figure 8 A and B shows the “redelivery” and “total” reproducibility for each QA 
system measured on each patient plan, where the total reproducibility includes the overall 
uncertainty from setup, delivery, and readout of results.  The coefficient of variation 
describes the variability in the absolute dose measurement (for the ion chamber readings) or 
the percent of pixels passing gamma (for the planar/array devices). A salient feature of these 
plots is the heterogeneity in a dosimeter’s coefficient of variation (CV) across the different 
plans.  While the plan “Thor 3” showed the overall highest CV for both the “redelivery” and 
“total delivery”, no plan-based statistical difference was found when an ANOVA was run 
(p-value of 0.88).  This indicates that plan-dependent characteristics were not particularly 
important in terms of device reproducibility. Rather, reproducibility was determined more 
by the device as detailed below. 
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 Figure 8A, shows the variety of “redelivery” reproducibility exhibited by the 
different devices due to readout and machine fluctuations, and analysis.  This bar plot shows 
the CV’s for each device grouped by IMRT plan. Most devices except film demonstrated 
consistent QA results, as shown by the relatively small bars.  Overall, the AP field-by-field 
MapCheck displayed the lowest variability in its measurements. The AP composite 
MapCheck can be seen to have a very low coefficient of variation, and in fact, has a 
“redelivery” coefficient of variation of 0% for three plans (the exact same percent of pixels 
passing were obtained for each delivery under the same setup).  In contrast, the radiographic 
film generally had much higher variability in the measurements. Apart from film, all other 
QA systems showed a less than 1% variation for “redelivery” reproducibility (Figure 8A), 
indicating little variation in the delivery/readout portion of the QA.   
 
 
 
 
 
 
 
 
 
 
33 
 
 
 
Figure 8 “redelivery” and “total” reproducibility (CV) for each dosimeter system, 
grouped by patient plan.  All methods showed a CV of less than 4%, with film 
demonstrating the highest variability for both delivery/readout and total 
reproducibility, where total reproducibility includes variation from both the 
delivery/readout and setup 
 
 
 The “total delivery” reproducibility is displayed in Figure 8B, and shows a greater 
spread in device performance.  This relationship shows how the reproducibility of these 
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devices may have similar consistency in the read out of their results, but their different 
setups can lead to QA system-based differences in the constancy of QA results. 
 To examine specifically the devices’ performance, the CV’s for each patient plan 
were averaged across each device.  Figure 9A displays the “redelivery” average CV per 
device (blue bars) with the standard error shown as error bars.  Figure 9B similarly shows 
the “total delivery” average CV (red bar) with standard error bars.  Figure 9A shows that the 
radiographic film demonstrates a clearly higher variability in QA results compared to the 
other dosimeter systems. An ANOVA was performed with a post hoc Tukey HSD test, 
which indicated that of the CV’s from the “redelivery” measurements, radiographic film was 
the only device that was statistically different from the other dosimeters (p-value of 0.0001).  
Figure 9B shows the “total” variability among devices, with larger and more variable values 
being apparent. This indicates how variability from delivery/readout is relatively higher than 
the setup in film compared to other dosimeters. An ANOVA was performed with a post hoc 
Tukey HSD test on the “total” variability. Two groups of devices were apparent, with two 
devices (ArcCheck and MapCheck with original gantry angles delivered) not being 
significantly different from either group (p-value of 0.004). This is illustrated in a Venn 
diagram (Figure 10). Film was again the most variable device, but was not statistically 
different from all other techniques, as was the case in “redelivery” reproducibility.   
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Figure 9 patient-averaged “redelivery” (blue) and “total” (red) reproducibility (CV) 
for each device.  The errors bars are given as standard error.  The film shows the 
highest variability of all the devices. 
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Figure 10 Venn Diagram showing statistically significant grouping of dosimetric 
systems based on their “total” reproducibility.  The CV of film was significantly 
different from the cc04 ion chamber, MapCheck with AP beams formed into a 
composite plane, MapCheck with AP beams analysed in a field-by-field analysis, and 
the multiple ion chamber phantom (MIC).  The CV’s of the ArcCheck and the 
MapCheck with the original rotational gantry angles were not significantly different 
from either group. 
 
 When assessing the reproducibility of the QA systems, there is a difference in how 
much variability is contributed from setup and from delivery/readout.  Each device showed 
different sensitivities to these two sources of variability.  The “redelivery” measurement 
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captures the reproducibility from readout/delivery, while the “total” measurement contains 
contributions from both the setup and readout/delivery.  Therefore, the setup reproducibility 
was calculated through the use of the “total” and “redelivery” measurements in Equation 6.  
From these values, the degree of influence from delivery/readout and setup can be evaluated.  
These results are summarized in Table 1.  From this table, it can be seen that film is the only 
dosimeter with a higher delivery/readout contribution than the setup (59% vs. 41%).  All 
other QA systems show a much greater variability stemming from the setup, with the 
rotational MapCheck demonstrating the highest (97% from setup vs. 3.0% from 
delivery/readout).  It is of interest to note that the same physical dosimeter setup was used 
for AP field-by-field, rotational, and AP composite MapCheck.  However the differences in 
the way the results were obtained and analyzed has led to different degrees of sensitivity to 
setup and readout/delivery.  For example, the variability in the AP composite MapCheck and 
MapCheck with original gantry angles delivered shows a higher dependence on the setup 
than the AP field-by-field MapCheck.  Additionally, the values of the CV’s averaged across 
patient plans shows a lower variability in the AP field-by-field MapCheck than in its other 
two configurations.   
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Table 1 Isolating the error caused by setup alone from the redelivery and total 
coefficients of variation averaged across all patient plans 
 
 
“redelivery” 
measurement 
CV 
setup 
CV 
“total 
delivery” 
measurement 
CV 
% 
variation 
from 
delivery/re
ad-out 
% 
variation 
from 
setup 
AP field-by-field Mapcheck  0.09% 0.12% 0.15% 37% 63% 
rotational MapCheck  0.24% 1.3% 1.4% 3.0% 97% 
cc04 ion chamber  0.13% 0.33% 0.36% 13% 87% 
radiographic film 1.5% 1.3% 2.0% 59% 41% 
MIC IC Avg  0.25% 0.38% 0.46% 31% 69% 
ArcCheck  0.36% 0.94% 1.0% 13% 87% 
AP composite Mapcheck  0.14% 0.44% 0.46% 8.7% 91% 
 
 
 Ion chamber measurements are generally the most trusted.  In clinical practice, this 
reliability is assumed to be partially dependent on the standard deviation of the dose as 
calculated across the ion chamber volume ROI.  The common guidance for the placement of 
an ion chamber measurement is to put it in a high dose, low gradient region.  The dose is 
usually assessed by seeing what percent of the plan maximum dose the average dose across 
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the ion chamber is.  The gradient is assessed by calculating the standard deviation in the 
dose across the ion chamber ROI.  As an additional analysis into the nature of QA 
reproducibility, this assumption was studied by comparing the percent standard deviation in 
the reproducibility measurements across the six patient plans with the percent standard 
deviation in the dose across the ion chamber ROI in the TPS.  Using a linear model to fit the 
percent standard deviation in the measurement data to that found in the ROI, 95% prediction 
confidence bands were calculated for the ability to predict a percent standard deviation in 
the measurement based on the percent standard deviation calculated across the ion chamber.  
Because an arbitrary measurement includes setup uncertainty, this work only evaluated the 
results of the dose standard deviation compared to the “total delivery” reproducibility.  
These results are shown in Figure 11.  The R-squared value for this model is only 0.36, 
showing very little linear relationship.  This plot also shows that the prediction bands are 
wider than the plot in some places, revealing a lack of prediction power – that is, this 
research failed to show an ability to predict the reproducibility of a measurement from the 
standard deviation in the dose across the ion chamber.   The analysis was done again with 
expansions of the ROI ion chamber volume by 1, 2, 3, and 5mm to attempt to capture any 
effects from the local dose environment.  Again, these showed little relationship between 
these two features, with R-squared values of 0.39, 0.41, 0.42, and 0.41 for the 1, 2, 3, and 
5mm expansions, respectively (Table 2).   
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Table 2 The results of the regression analysis for 0, 1, 2, 3, and 5mm expansions 
around the ion chamber volume compared to resetup standard deviation 
expansion on IC ROI 
(mm) R-sqr 
F-
statistic p-value 
0 0.36 16.04 0.0004 
1 0.39 18.03 0.0002 
2 0.41 19.23 0.0001 
3 0.42 20.3 0.0001 
5 0.41 19.41 0.0001 
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Figure 11 Regression performed to see the ability to predict percent “total” 
reproducibility given a known percent standard deviation in dose across the ion 
chamber.  This percent standard deviation in dose is used to assess the severity of the 
dose gradient across the ion chamber. The inner pair of dotted lines is the confidence 
interval in the linear fit, while the outer pair of lines is the prediction confidence 
interval.   
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An additional examination of the ion chamber data also failed to show a relationship 
between total reproducibility and the percent of the plan maximum dose in the ion chamber 
ROI (Figure 12).  This plot shows that the percent standard deviation mildly decreases as the 
dose increases in the ion chamber active volume.  However, this regression line was not 
shown to be statistically significant (p-value of 0.74), revealing a lack of linear fit in the 
data.  Looking at the data points themselves, it is worth noting that even at a high percent of 
the maximum dose (i.e. 96% of the plan’s maximum dose), there is a possibility of seeing a 
non-zero percent standard deviation in the total reproducibility (i.e. 0.86%). 
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Figure 12 A regression analysis exploring whether knowing the percent of the plan’s 
maximum dose in the chamber ROI can predict the “total” reproducibility in the 
measurement is shown.  As with the standard deviation in the dose study, the inner 
pair of dotted lines is the 95% confidence interval in the linear fit, while the outer pair 
of lines is the prediction confidence interval.   
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8.4 Discussion 
 Performing a reproducibility study on different patient specific IMRT QA equipment 
and methods shows a comparison in the potential for variation in QA results.  The most 
salient finding was the lower reproducibility in EDR2 film, which was significantly different 
from the other methods in both the “total delivery” (a coefficient of variation of 2.0%) and 
“redelivery” (a coefficient of variation of 1.5%) studies.  This is most likely influenced by 
the high degree of human interaction involved in the readout and analysis of the film 
performed at the author’s institution.  The user has input on aligning the film to the 
calculated dose plane.  The user also selects an ROI for the gamma analysis and can choose 
a normalization point from any location in the dose plane.  No other QA method in this 
publication’s study allowed for as much user latitude.  An additional aspect inherent to film 
is the variation introduced from the film processing.  Time before developing and developer 
conditions can all influence the optical density of film (Childress 2005).   
 There were two types of reproducibility measured: “redelivery” and “total delivery.”  
When the patient plan CV’s are averaged per device, the “total delivery” reproducibility was 
generally higher than the “redelivery” reproducibility since it includes variation from both 
delivery/readout and setup.  After extracting the setup reproducibility from the “total 
delivery,” it was seen that the setup was more responsible for the variability than the 
readout/delivery.  The only exception to this was the radiographic film, with its more 
involved readout.  The “total delivery” study most closely mimics what a clinic could expect 
as the equipment is setup from day to day to perform QA.  The “redelivery” study represents 
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what kind of variation would be seen if nothing was moved and only the plan was 
redelivered.  In the clinic, when a plan gives suspicious QA results, sometimes it is 
redelivered with the assumption that there was some error in the initial delivery.  This study 
shows what kind of variation could be expected from simply retaking the plan again.  For 
example, if radiographic film is your dosimeter and you set it up again for another 
measurement, you could obtain a 1% higher result in percentage of pixels passing.  It is 
important to notice that on average the coefficients of variation in the redelivery study are 
non-zero across all devices investigated, showing that there is some variability inherent in 
the delivery and readout, itself. 
 Apart from film, none of the other methods are significantly different in their 
coefficients of variation for the “redelivery” reproducibility.  These other 6 methods have 
immediate readout capabilities, minimizing the degree of human interaction.  However, this 
homogeneity decreases for the “total” reproducibility.  The Tukey HSD test divides the 
methods into two significant groups (labeled group A and B in Figure 10), with two methods 
belonging to both groups.  All of the methods in Group A of Figure 10 consist of a rotational 
delivery to a planar dosimeter.  Because this grouping appears in the “total delivery” 
reproducibility results, the planar measurements with original gantry angles appear to be 
more sensitive to setup errors than when the fields are delivered perpendicularly.  This may 
be due to the fact that there is an increase in the degrees of freedom in the motion of the 
dosimeter relative to the delivery of the beam.  All point measurements and AP planar 
measurements belong in Group B with lower coefficients of variation.  Within the Group B 
exhibiting low variability, the AP composite MapCheck’s higher CV may be due to the fact 
that any discrepancies in each field have been combined together.  The AP field-by-field 
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MapCheck shows the lowest variability.  This might be from a combination of the ease of 
setup and the lower degrees of freedom of motion between the dosimeter and beam delivery.   
 In the portion of this study investigating the relationship between the variations 
calculated in the dose across the ion chamber and the variation in the measurement, we 
failed to find a significant relationship between these two characteristics.  In fact, the highest 
adjusted R squared value showed that the variation in dose across the ion chamber could 
only predict 42% of the variation witnessed in the “total delivery” measurements. Similar 
analysis with expansions around the ion chamber ROI of 1, 2, 3, and 5mm showed that even 
when incorporating the local dose environment, we were unable to prove a significant 
relationship between standard deviation in the dose across the ion chamber ROI and 
reproducibility.   
Prediction intervals were also calculated to judge the range of expected measurement 
reproducibility given a certain choice of percent standard deviation in dose across the ion 
chamber.  Because this was done as follow-up analysis and not a primary goal of this study, 
most of the data is clustered below 2% standard deviation across the chamber. 
Consequently, the confidence interval is wide and there is little data at large standard 
deviations. Nevertheless, some information may be gleaned from this data.  For a 0mm 
expansion around the active volume, a standard deviation in dose of less that 2% should lead 
to a standard deviation in your measurement of less than 1%. Of note, even a point with 
virtually no gradient across the chamber can still readily show a measurement 
reproducibility of nearly 1%.    
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8.5 Conclusion 
By analyzing the coefficients of variation across seven different methods of patient-specific 
IMRT QA, the goal of this research was to provide a comparison of the reproducibility of a 
QA measurement. In terms of reproducibility all methods demonstrated coefficients of 
variation less than 4%, both for delivery/readout and for the total reproducibility.  Film 
performed the poorest, with an average coefficient of variation across all plans of 1.5% for 
delivery/readout and 2% for total reproducibility (including delivery/readout and setup).  
Excluding film, the next largest average CV was 0.36% (ArcCheck) for delivery/readout 
reproducibility, and 1.4% (planned angle MapCheck) for the total reproducibility.  When the 
setup reproducibility was extracted from the measurements that looked at the total 
reproducibility, it was seen that the setup contributes a greater amount of variability than the 
delivery/readout for all QA methods except film.  This could be explained by the fact that 
film’s readout is less automated than the other methods.  With the data provided from this 
study, a clinic can have a greater insight into the expected reproducibility of their patient-
specific IMRT QA with respect to the dosimeter and method employed.    
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I. Chapter 4 
Towards an Optimization of Patient-Specific IMRT QA Techniques 
4.1  INTRODUCTION 
Intensity modulated radiation therapy (IMRT) is a commonly practiced form of radiation 
therapy. Because of the complexity of this treatment technique, verification of patient plans 
is performed via direct measurement, called patient-specific IMRT quality assurance (QA). 
Despite the widespread practice of IMRT QA, its implementation has not been standardized, 
and many methods and types of equipment exist to accomplish it (Nelms 2007). With such 
heterogeneity in the field, we asked whether the efficacy among the various methods is 
equal or whether there is an optimal way to perform IMRT QA with the goal of 
distinguishing between acceptable and unacceptable plans. This is further complicated by it 
not only being a question of the detector used in performing IMRT QA; but also of how the 
data should be is analyzed. Whereas ion chamber measurements typically rely on a percent 
dose difference cutoff, gamma analysis for planar QA relies on three parameters: percent 
dose difference, distance to agreement, and percent of pixels passing (Low 1998). 
Additionally, multiple software packages exist for gamma analysis, which may implement 
the calculation differently. 
Insight into this question can be achieved by evaluating various IMRT QA 
techniques using receiver operating characteristic (ROC) curves, which can address the 
question of performance for both hardware and the methodologies used (DeLong 1988). 
Recently published comments have called attention to the apt application of ROC analysis as 
a quantitative means of assessing the practice of patient-specific IMRT QA (Gordon 2013). 
In ROC analysis, a curve of the sensitivity and specificity of a test is plotted as the values of 
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the cut-off are varied. In this study, sensitivity is the ability of a dosimeter to accurately label 
an unacceptable plan as failing; conversely, specificity is the ability to label an acceptable 
plan as passing. Cutoff values in this study were the percent of pixels passing for gamma 
analysis and the percent difference for ion chamber measurements. There is an inherent 
trade-off in these two parameters: as the cutoff is rendered more stringent to increase 
sensitivity, the specificity decreases. A ROC curve gives the user a convenient, holistic view 
of these trade-offs across all cutoffs. An example ROC curve is shown in Figure 13, where 
the vertical axis is sensitivity (range, 0 to 1), and the horizontal axis is 1 – specificity (range, 
1 to 0). The ROC curve for an ideal dosimeter that perfectly sorts patient plans, which is also 
shown in this figure, has an area under the curve (AUC) equal to one. In contrast, a 45 
degree diagonal line (AUC equals 0.5) represents a dosimeter that sorts plans completely 
randomly. The AUC is a useful metric with which to determine the performance of a device 
over the entire range of cutoff values. This AUC is also equivalent to the probability that for 
a randomly selected acceptable and unacceptable plan, the dosimeter correctly classifies 
these two plans as passing and failing. A detailed explanation of ROC techniques is well 
explained in the literature (Metz 1978). 
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Figure 13 ROC curve given as an example. This type of plot shows the ability of a test 
to accurately sort incidents, where the true state is determined by a gold standard. The 
vertical axis shows sensitivity, whereas the horizontal axis shows specificity. The 
thicker red line shows a test with perfect classification, whereas the thinner blue line 
shows what a realistic ROC curve would look like for a test. The diagonal grey line is 
the ROC curve that would result from a test with random classification. 
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One recent study examined a diode array’s optimal cutoffs through the lens of ROC 
analysis (Carlone 2013). Many other studies have also explored this large question of 
optimal IMRT QA criteria (Nelms 2007; Howell 2008; Wilcox 2008; Kruse 2010). 
However, none have applied this analysis technique to study a broad range of dosimeters, 
comparing not only the hardware, but also the protocol used in the setup and analysis. 
Consequently, the relative performance of various QA techniques remains unclear. To this 
end, this research uses ROC analysis to discover which, if any, of the most commonly used 
QA procedures perform most robustly in terms of both their sensitivity and specificity, and 
what optimal cutoffs can be gleaned from these ROC curves. More specifically, we 
investigated the abilities of the MapCheck2 in a variety of configurations, ArcCheck, 
radiographic film, and an ion chamber using original clinical patient plans to generate 
clinically relevant comparisons. 
 
4.2 METHODS 
4.2.1 Patient selection 
Twenty-four clinical patient plans were selected from our database of previously 
delivered patient-specific IMRT QA plans at our institution. To more rigorously test the 
performance of various QA dosimeters, most of these plans (19) were selected from a group 
that had previously failed film and ion chamber QA at the authors’ institution (<90% pixels 
passing at 5%/3mm, or an ion chamber reading of >3% dose difference). These plans were 
not modified to artificially create failing cases; instead they were true clinical IMRT plans 
created with the intent of patient delivery. Since it is highly difficult to predict all possible 
failure modes in IMRT plan delivery, it was believed that actual patient plans would be 
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more insightful than using induced errors. The remaining 5 plans previously passed IMRT 
QA. In addition, a variety of treatment sites (thoracic, gastrointestinal, head and neck, 
stereotactic spine, gynecologic, mesotheliomal, and genitourinary) were selected to ensure 
that the scope of dosimeter performance would reflect the variety of plans seen in the clinic. 
All of the plans were calculated in the Pinnacle
3
 9.0 treatment planning software (TPS) 
(Phillips Healthcare, Andover, MA). The clinical acceptability of each plan was determined 
on the basis of measurements in a multiple ion chamber phantom (described below). Then, 
each plan was delivered to a variety of dosimeters to assess the performance of each 
dosimeter. 
 
4.2.2 Dosimeters 
Multiple ion chamber phantom 
An in-house designed multiple ion chamber phantom (Figure 14) was selected as the 
gold standard with which to classify a plan as acceptable or unacceptable. This sorting of 
plans into acceptable or unacceptable was considered the “true” sorting and was based solely 
on the results of the multiple ion chamber phantom; such sorting was unrelated to the 
original internal IMRT QA results. The performance of all of the other dosimeters was 
compared with the classification results of the multiple ion chamber phantom. 
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Figure 14 Multiple ion chamber phantom irradiation setup. This phantom contains 
five ion chambers placed in an insert that can rotate to eight positions. The ion 
chambers are located at 3-dimensionally independent locations to better sample the 
IMRT QA. This phantom was used as the gold standard for this study. 
 
The ion chamber is accepted as a reliable benchmark in radiation therapy dosimetry 
(Bogner 2004); however it is only a point measurement. To more fully evaluate each plan, 
the multiple ion chamber phantom was created with five ion chambers (Exradin A1SL 
0.057cc) positioned at unique depths, heights, and lateral positions within a cylindrical 
insert. This insert can rotate to eight different positions, allowing a large number of points to 
be three-dimensionally sampled. All 24 patient plans were delivered at the original gantry 
angles with two different insert rotations, leading to 10 ion chamber readings per patient 
plan. The phantom’s insert rotational positions, along with shifts to the phantom, were made 
to maximize the number of points that fell within a high-dose, low-gradient region. Each ion 
chamber was calibrated by an Accredited Dosimetry Calibration Laboratory, and the 
absolute dose was determined at each measurement location. This dose was then compared 
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with the dose calculated by the planning system over the volume corresponding to the active 
volume of the ion chamber. 
Although the definition of a truly acceptable versus unacceptable plan is ultimately a 
matter of clinical judgment, the use of multiple ion chamber measurements as the gold 
standard with which to classify plans has been previously used in IMRT QA comparisons 
(Kruse 2010). 
Each plan was then also delivered to the dosimeters listed below to assess the sorting 
performance of each.  The algorithm used to transform measurements from the multiple ion 
chamber phantom to a label of acceptable or unacceptable for each IMRT plan is more fully 
explained in APPENDIX III. 
 
MapCheck 
A diode array (MapCheck2, Sun Nuclear Corporation, Melbourne, FL) with 5-cm 
water equivalent buildup was used to measure the delivered dose distribution in three 
separate ways. The first method was a field-by-field analysis with all of the plans’ beams 
delivered with a gantry angle of zero degrees (anterior-posterior field). The percent of pixels 
passing per field were combined by using an MU-weighted average to provide a single value 
of percent of pixels passing for all of the fields. The second method combined all of the AP-
delivered fields into a composite measurement and compared that with the composite 
calculated dose plane. The third method delivered all of the fields at their original rotational 
gantry angles with the MapCheck placed in the MapPhan phantom. 
Because most of the original gantry angle fields did not enter laterally, the plans 
were delivered with the diode array flat on the treatment couch (as per the manufacturer’s 
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instructions). For all MapCheck configurations, the diodes were calibrated for absolute dose 
and corrected for accelerator daily output fluctuations. Plans on all three methods underwent 
gamma analysis (Low 1998) at 2%/2mm, 3%/3mm, and 5%/3mm using both SNC Patient 
software (Sun Nuclear Corporation, Melbourne, FL) and DoseLab Pro software (Mobius 
Medical Systems, Houston, TX). With SNC Patient, the region of interest (ROI) accounted 
for the known locations of the diodes, whereas with DoseLab Pro, the ROI was 
automatically selected. In both software packages, the TPS was used as the evaluated 
distribution in the gamma analysis. 
 
Film and ion chamber 
Radiographic film (Kodak EDR2) and a single ion chamber (Wellhofer cc04) were 
placed in an I’mRT body phantom (IBA Dosimetry, Schwarzenbruck, Germany). The plans 
were all delivered with their original gantry angles. Due to inherent differences in the types 
of measurement (point vs. planar, absolute dose vs. relative dose), the ion chamber and film 
were analyzed as two separate dosimeters, although their measurements were taken 
simultaneously. The ion chamber was placed in a position with a standard deviation across 
the ion chamber ROI of less than 1% of the mean dose, and a mean dose of greater than 70% 
of the maximum dose in the plan. Shifts to the phantom were applied if necessary to satisfy 
these criteria. The absolute dose was determined from a transfer factor applied to the 
electrometer reading, corrected for daily output of the accelerator, and compared with the 
dose calculated by the planning system over the volume corresponding to the active volume 
of the ion chamber. 
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The film evaluated a transverse plane of the delivered dose distribution. It then 
underwent gamma analysis in the Omnipro I’mRT software (IBA Dosimetry, 
Schwarzenbruck, Germany) at 2%/2mm, 3%/3mm, and 5%/3mm, all with a 10% dose 
threshold. In this software, the ROI was manually selected to be the area of the film 
contained within the phantom, and the TPS was selected to be the reference distribution in 
the gamma analysis. The film optical density was converted to dose with use of a batch-
specific calibration curve and spatially registered with use of pin pricks. The film was then 
used as a relative dosimeter with the normalization point manually selected to maximize 
agreement with the calculated plane. 
 
ArcCheck 
The ArcCheck (Sun Nuclear Corporation, Melbourne, FL) cylindrical diode array 
was treated with the electronics facing away from the linear accelerator. As with the 
MapCheck, the array was calibrated for absolute dose. If necessary, shifts were applied to 
the ArcCheck to avoid irradiating the electronics. Gamma analysis was performed in the 
SNC Patient software at 2%/2mm, 3%/3mm, and 5%/3mm, with a 10% dose threshold. 
 
4.2.3 Data analysis 
First, we defined which plans were acceptable and which were unacceptable based 
on the multiple ion chamber measurements. A gold standard need not be infallible, but it 
must be considerably more accurate than, and independent of, the tests being evaluated 
(Metz 1978). The 10 ion chamber points measured on each patient plan were pruned down 
to include only those that satisfied the criteria of an ROI mean dose of at least 50% of the 
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maximum plan dose and a standard deviation of less than 1% of the mean dose across the 
ion chamber ROI, i.e., points in a relatively high dose and low-gradient region. These ion 
chamber measurements were then compared with their expected values calculated in the 
TPS. The deviations at the points showing a greater than 3% dose difference were summed 
together and then normalized by the number of points in high-dose, low-gradient regions 
used to assess the plan. This final value is in essence an average deviation metric and was 
the metric that was used to summarize the ion chamber measurements for each plan into one 
value, accounting for the varying number of points per plan remaining after the dose and 
standard deviation criteria.  
Based on hierarchical clustering (Hastie 2009), a plan was classified as acceptable if 
its multi-ion chamber metric was less than 0.30; a plan was considered unacceptable if this 
metric was greater than 0.30. Although this cutoff threshold was defined on the basis of the 
arbitrary inclusion criteria of only those points receiving >50% of the maximum dose and 
<1% standard deviation across the chamber, this threshold was actually quite robust; plans 
were sorted identically based on any inclusion of points between 25% and 65% of the 
maximum dose and up to 2% standard deviation. Moreover, multiple ion chamber readings 
were also used as a gold standard in work by Kruse, in which he classified a plan as failing 
if any individual ion chamber measurements differed by greater than 4% (Kruse 2010). 
Interestingly, his methodology sorts our data set’s plans in the same way that the method 
used in our study does.  The method used in this research is shown in APPENDIX III. 
Once the plans were sorted into acceptable and unacceptable plans, the ability of 
each alternate dosimeter to correctly sort the plans could be conducted. This was done by 
using ROC analysis. ROC curves were formed by comparing the passing and failing results 
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of each dosimeter system on the set of 24 acceptable and unacceptable patient plans. These 
curves have a staircase-like pattern due to the finite number of cases considered. Because of 
its independence from the prevalence of unacceptable plans, sensitivity weighting, and 
specificity weighting, the AUC statistic is commonly used to compare different ROC curves 
(DeLong 1988). It was therefore used here to compare each device’s discriminating 
capabilities. Confidence intervals were calculated with the use of the bootstrap method 
implemented in the pROC R package (Robin 2011). Bootstrapping was also applied to 
compare the AUCs using the “Z” statistic and by obtaining p-values to determine whether 
pairs of AUCs were significantly different (Robin 2011).  An explanation of bootstrapping is 
found in APPENDIX II. 
ROC curves are generated by considering all possible thresholds (e.g., all ion 
chamber dose difference thresholds, or all percent of pixels passing for a given dose 
difference and distance to agreement criteria). Once a ROC curve has been generated, a 
natural follow-up is to find the value on the curve (e.g., what percent of pixels passing 
threshold) that provides the best discriminatory power. Optimal cutoff criteria and their 
accompanying confidence intervals were calculated in the R statistical packages pROC 
(Robin 2011) and ThresholdROC (Skaltsa 2010). The Youden Index method was used, 
which finds the point along the curve farthest from the diagonal random guess line (Perkins 
2006). The Youden Index has been shown to be a more robust optimization method than is 
finding the point closest to perfect classification (0,1) (Perkins 2006). However, this optimal 
point may not accurately reflect practical realities. For example, if the prevalence of a failing 
plan is low, having an overly sensitive cutoff could lead to an excessive number of false 
positives (i.e., acceptable plans labeled as failing), wasting time in the clinic. Conversely, if 
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the cost related to passing an unacceptable plan is high, a sensitive cutoff would be favored 
over one with high specificity. Therefore, the optimal cutoff values were calculated with use 
of the ThresholdROC package by minimizing a cost function that incorporates the cost of 
false negatives and prevalence (Skaltsa 2010). The prevalence of a failing plan was 
estimated at 3% based on the work by Dong (Dong 2003). The cost values are dependent on 
the situation at a particular clinic and can include such factors as the risks of delivering a 
failing plan to a patient, tempered by the extra time demanded in the clinic if an acceptable 
plan is falsely labeled as failing. To estimate a common cost metric reflected in clinical 
practice (e.g., a 3% acceptance criteria with an ion chamber), the cost was varied until the 
optimal cutoff of 3% was generated for the cc04 ion chamber (Ezzell 2003). This cost 
weighting was then used to determine the equivalent threshold (i.e., using the same cost 
weighting) for the other dosimeters examined. 
 
4.3 RESULTS  
Each of the 24 plans was delivered to the multi-ion chamber phantom. After pruning 
data points to exclude those with low doses or high dose gradients, the average number of 
ion chamber measurements per patient plan was 6, with a minimum of 4 and a maximum of 
9. This gold standard ultimately sorted the 24 plans into 9 acceptable and 15 unacceptable 
plans, yielding a good distribution of plan challenge levels on which to rigorously test the 
different QA systems. 
After delivery of these 24 plans to each QA device, ROC curves were created. As an 
example, Figure 15 shows the ROC curve generated for the single cc04 ion chamber in the 
I’mRT phantom (Sing 2005). The numbers printed on the curve are the cutoff values (in % 
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dose difference). Across the 24 patient plans, the percent difference for the ion chamber 
ranged from 0% to 4.5%. As would be expected, as the cutoff increased from more liberal 
(4.5%) to more stringent (0.5%), the sensitivity increased (i.e., the device was better at 
detecting and failing unacceptable plans). Concurrently, the specificity decreased (i.e., the 
device was less adept at passing acceptable plans). The curve for this dosimeter lies well 
above the “random guess” diagonal line, showing an overall strong ability to discriminate 
between acceptable and unacceptable plans. 
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Figure 15 ROC curve for the cc04 ion chamber. This plot shows how the ROC curve is 
generated by varying the cutoff values from more to less stringent. The percent dose 
difference cutoff values used to create the curve are numerically printed on the curve 
and also color coded, using a spectrum with red being the least stringent and blue 
being the most. 
 
An ROC curve was generated for each QA system, and in the case of the planar 
measurements, for gamma criteria of 2%/2mm, 3%/3mm, and 5%/3mm, leading to 16 
curves shown in Figure 16. The MapCheck curves shown in Figure 16 include only gamma 
analysis results from the SNC Patient software. Of those curves, the MapCheck with original 
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rotational gantry angles delivered (Figure 16a) consistently fell close to the diagonal line, 
indicating poor discriminatory abilities. Similarly, the MapCheck curves for field-by-field 
AP beam delivery also fell close to the diagonal line (Figure 16b). In contrast, ROC curves 
that were relatively far from the diagonal line were the MapCheck with all AP fields formed 
into a composite dose plane (Figure 16c), the cc04 ion chamber (Figure 16d), the ArcCheck 
(Figure 16e), and film (Figure 16f), indicating a relatively strong ability to discriminate 
between acceptable and unacceptable plans.  
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Figure 16 ROC curves generated for each analysis, grouped by dosimetric system. For 
each planar dosimeter, each panel contains an ROC curve for 2%/2mm, 3%/3mm, and 
5%/3mm as the criteria for the gamma analysis. For this figure, all MapCheck gamma 
analysis was performed using SNC Patient. 
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Each panel in Figure 16 (except the single ion chamber) contains multiple curves, 
one each for 2%/2mm, 3%/3mm, and 5%/3mm. These three different curves are generated 
by varying the cutoff criteria (percent of pixels passing for the gamma analysis) from very 
liberal to very conservative such that the curve begins at the bottom left and ends at the top 
right, respectively. Each curve is formed from a different range of percent of pixels passing 
(or percent difference in the case of the ion chamber). A D-test performed with 2000 
replicates bootstrapped to the data in the pROC package compared the planar measurements 
at 2%/2mm, 3%/3mm, and 5%/3mm for each device. Due to the fact that several one-to-one 
comparisons were performed, there is a probability that one would obtain statistical 
significance by chance. To correct for this, a False Discovery Rate (FDR) correction was 
applied to the data. However, even without the correction, none of the devices evaluated 
showed significant differences (alpha = 0.05) in their AUC among the three dose difference 
and distance to agreement criteria. This suggests that different gamma criteria can be used at 
various cutoff values to obtain similar discrimination ability. Clinically, there may still be a 
practical reason to have a preference between these thresholds. For example, for looser 
criteria (e.g., 5%/3mm), in order to obtain a similar sensitivity and specificity, the cutoff 
value may have to be set impractically high (i.e., more than 99% of pixels passing). 
Nine additional MapCheck curves were created for gamma analyses conducted in 
DoseLab Pro. Figure 17 shows the comparison between SNC Patient analysis and DoseLab 
Pro analysis with the 3%/3mm criteria (other criteria not shown). For all criteria, a D-test 
was performed with 2000 replicates bootstrapped to the data. After application of a false 
discovery rate correction, there were no significant differences between SNC Patient and 
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DoseLab Pro analysis in terms of AUC for any of the evaluated devices. However, the 
curves are clearly not superimposed, which is the result of variations in the two software 
packages, such as different implementations of measured and calculated plane alignment, 
methods of dose thresholding, and ROI selection. The choice in details of implementing the 
gamma analysis can lead to different results (Ezzell 2009).  
  
66 
 
 
 
 
Figure 17  Comparing gamma 
calculations between DoseLabPro 
(solid red line) and SNC Patient 
(dashed blue line) for ROC curves 
created from the MapCheck 
measurements analyzed at 3%/3mm. 
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The AUC summarizes the overall ability of a QA system to accurately identify acceptable 
and unacceptable plans across all dosimeter criteria and cutoff values. The maximum value 
the AUC can assume is 1 (perfect classification of plans), whereas an AUC of 0.5 is 
equivalent to a random guess. The best-performing QA system was the single ion chamber 
with an area of 0.94 (0.82, 1.0), followed by the composite MapCheck at 5%/3mm with all 
fields delivered AP: 0.93 (0.80, 1.0). The worst performer was the MapCheck field by field 
at 5%/3mm with all beams delivered AP: 0.55 (0.31, 0.79). All AUC’s with confidence 
intervals are shown in Table 3 in order of decreasing AUC. 
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Table 3 Areas under the curves for all dosimetric systems and analysis techniques, with 
accompanying bootstrapped 95% confidence intervals  
IMRT QA Method AUC  
 
C.I. 
 
cc04 ion chamber 0.94 ( 0.82 - 1.00 ) 
AP composite MapCheck at 5%/3mm (DL) 0.93 ( 0.80 - 1.00 ) 
AP composite MapCheck at 3%/3mm (DL) 0.89 ( 0.73 - 1.00 ) 
ArcCheck at 5%/3mm (SNC) 0.87 ( 0.71 - 0.99 ) 
AP composite MapCheck at 2%/2mm (DL) 0.85 ( 0.67 - 0.99 ) 
AP composite MapCheck at 3%/3mm (SNC) 0.85 ( 0.66 - 1.00 ) 
EDR2 film at 5%/3mm 0.84 ( 0.66 - 1.00 ) 
EDR2 film at 3%/3mm 0.84 ( 0.66 - 0.97 ) 
ArcCheck at 3%/3mm (SNC) 0.84 ( 0.67 - 0.99 ) 
ArcCheck at 2%/2mm (SNC) 0.81 ( 0.61 - 0.95 ) 
AP field-by-field MapCheck at 2%/2mm (DL) 0.80 ( 0.61 - 0.98 ) 
AP composite MapCheck at 2%/2mm (SNC) 0.80 ( 0.60 - 0.95 ) 
AP composite MapCheck at 5%/3mm (SNC) 0.78 ( 0.57 - 0.92 ) 
AP field-by-field MapCheck at 3%/3mm (DL) 0.76 ( 0.51 - 0.97 ) 
EDR2 film at 2%/2mm 0.76 ( 0.55 - 0.93 ) 
Rotationally delivered MapCheck at 5%/3mm (SNC) 0.75 ( 0.51 - 0.94 ) 
Rotationally delivered MapCheck at 3%/3mm (SNC) 0.69 ( 0.44 - 0.89 ) 
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Rotationally delivered MapCheck at 5%/3mm (DL) 0.67 ( 0.44 - 0.89 ) 
AP field-by-field MapCheck at 5%/3mm (DL) 0.65 ( 0.38 - 0.90 ) 
Rotationally delivered MapCheck at 2%/2mm (SNC) 0.65 ( 0.41 - 0.85 ) 
AP field-by-field MapCheck at 2%/2mm (SNC) 0.61 ( 0.36 - 0.85 ) 
Rotationally delivered MapCheck at 2%/2mm (DL) 0.59 ( 0.35 - 0.83 ) 
AP field-by-field MapCheck at 3%/3mm (SNC) 0.59 ( 0.35 - 0.84 ) 
Rotationally delivered MapCheck at 3%/3mm (DL) 0.58 ( 0.33 - 0.81 ) 
AP field-by-field MapCheck at 5%/3mm (SNC) 0.55 ( 0.31 - 0.79 ) 
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We next compared the capabilities of the IMRT QA systems independent of their 
data analysis. That is, because there was a lack of significant differences between criteria or 
analysis software, the AUCs were grouped. All of the AUCs were placed into one of six 
groups: cc04 ion chamber, AP composite MapCheck, ArcCheck, EDR2 film, AP field-by-
field MapCheck, and rotationally (original gantry angle) delivered MapCheck. An ANOVA 
was performed to look for differences between these groups, including a post hoc analysis 
using Tukey’s Honestly Significant Difference test. The ANOVA analysis found that at least 
one group was significantly different (p = 0.0001), whereas the HSD test was able to group 
devices at the alpha = 0.05 significance level. The better-performing group contained the 
cc04 ion chamber, AP composite MapCheck, ArcCheck, and EDR2 film, whereas the AP 
field-by-field and rotationally delivered MapCheck were in the poorer-performing group. 
The means of each group are shown in Table 4, with the thick line showing the divide 
between the two groups. The AUC means in the higher group ranged from 0.815 to 0.937, 
whereas the poorer group ranged from 0.654 to 0.661. 
Table 4 Average AUC for each device, irrespective of analysis method. The thick line 
indicates where the devices were significantly grouped based on AUC performance.  
QA System Average AUC across all analysis systems 
cc04 ion chamber 0.94 
AP composite MapCheck 0.85 
ArcCheck 0.84 
EDR2 film 0.82 
AP field-by-field MapCheck 0.66 
Rotationally delivered MapCheck 0.65 
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Cutoff criteria in the clinic (e.g., a 3% ion chamber criterion) can be based on what 
has emerged as traditional practice. However, by evaluating the ROC curves, 
mathematically optimal criteria can be determined. For example, a percent of pixels passing 
threshold can be selected to provide the optimal sensitivity and specificity for a device at a 
3%/3mm criteria. The optimal cutoffs as calculated from the Youden Index for gamma 
analysis across all planar systems at 2%/2mm ranged from 68.1% to 89.6%; at 3%/3mm it 
ranged from 85% to 98.1%; and at 5%/3mm it ranged from 96.3% to 99.8%; these findings 
demonstrated a general trend that a looser gamma criteria requires a more stringent cutoff 
(and vice versa). The optimal cutoff for each system investigated is shown in Table 5, with 
95% confidence intervals, each calculated from 2000 bootstrapped replicates. Some systems, 
in conjunction with loose gamma criteria, can have clinically unreasonably high “optimal” 
thresholds. For example, the AP field-by-field MapCheck at 5%/3mm (SNC) and the AP 
composite MapCheck at 5%/3mm (DL) had optimal cutoffs of 98.7% and 99.7%, 
respectively. For the AP composite MapCheck at 5%/3mm, three quarters of the plans 
measured had 99% of pixels passing or higher, leading to an ROC curve that was generated 
from clinically unreasonable high cutoffs. This will be generally true for liberal dose 
difference and distance to agreement criteria. Therefore, the performance of the ROC curves 
and calculated optimal cutoffs must be tempered by clinical realities. When the ROC curve 
is formed from plans with a higher percent of pixels passing (or lower percent dose 
difference in the case of the ion chamber), the optimal cutoff value will be generally higher.  
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Table 5 Optimal cutoffs given for all dosimetric systems, both with and without 
weighting by the prevalence of a failing plan and the cost of falsely labeling a failing 
plan as passing.  The calculation of confidence intervals was based on a normal 
approximation, so there is an opportunity to exceed parameter space.  
 
Youden Index 
Empirical cutoffs: 
Prevalence is 3%, and 
cost of FN is 0.06 times 
the cost of FP 
 
 
Device 
Threshold (no 
weighting) 
Threshold (with 
weighting) 
cc04 ion chamber 1.6 ± 1.1 3.0 ± 0.7 
AP composite MapCheck at 
5%/3mm (DL) 99.7 ± 0.4 96.4 ± 2.5 
AP composite MapCheck at 
3%/3mm (DL) 98.1 ± 2.4 81.5 ± 12.7 
ArcCheck at 5%/3mm (SNC) 96.3 ± 1.7 92.1 ± 6.1 
AP composite MapCheck at 
2%/2mm (DL) 89.2 ± 6.6 61.6 ± 18.9 
AP composite MapCheck at 3%/3mm 
(SNC) 97.7 ± 2.0 82.5 ± 13.1 
EDR2 film at 3%/3mm 97.0 ± 9.7 76.3 ± 8.2 
EDR2 film at 5%/3mm 99.8 ± 1.5 91.2 ± 5.7 
ArcCheck at 3%/3mm (SNC) 92.0 ± 7.1 69.2 ± 14.0 
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ArcCheck at 2%/2mm (SNC) 74.4 ± 14.2 49.2 ± 11.4 
AP field-by-field MapCheck at 
2%/2mm (DL) 89.6 ± 3.7 77.8 ± 6.0 
AP composite MapCheck at 2%/2mm 
(SNC) 82.4 ± 9.4 66.1 ± 10.2 
AP composite MapCheck at 5%/3mm 
(SNC) 99.6 ± 0.4 98.5 ± 0.7 
AP field-by-field MapCheck at 
3%/3mm (DL) 98.0 ± 2.6 92.0 ± 4.4 
EDR2 film at 2%/2mm 68.1 ± 15.0 59.8 ± 6.4 
Rotationally delivered MapCheck at 
5%/3mm (SNC) 98.5 ± 7.2 82.7 ± 11.9 
Rotationally delivered MapCheck at 
3%/3mm (SNC) 94.9 ± 9.5 70.1 ± 12.8 
Rotationally delivered MapCheck at 
5%/3mm (DL) 98.0 ± 5.0 84.8 ± 9.3 
AP field-by-field MapCheck at 
5%/3mm (DL) 99.4 ± 1.1 97.8 ± 1.6 
Rotationally delivered MapCheck at 
2%/2mm (SNC) 69.2 ± 18.5 53.7 ± 13.2 
AP field-by-field MapCheck at 
2%/2mm (SNC) 85.0 ± 7.7 71.7 ± 16.5 
AP field-by-field MapCheck at 96.0 ± 4.6 89.6 ± 7.2 
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3%/3mm (SNC) 
Rotationally delivered MapCheck at 
2%/2mm (DL) 79.6 ± 20.9 48.2 ± 23.2 
Rotationally delivered MapCheck at 
3%/3mm (DL) 85.0 ± 14.4 68.6 ± 15.8 
AP field-by-field MapCheck at 
5%/3mm (SNC) 98.7 ± 1.9 96.3 ± 2.4 
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The cc04 ion chamber was calculated to have an optimal cutoff of 1.6% via the 
Youden Index. This is considerably lower than the 3% threshold commonly used in the 
clinic and would perhaps cause an intolerably high false-positive rate (i.e., failing acceptable 
plans).  However, this value was obtained without consideration of prevalence of 
unacceptable plans or cost of a false positive. These unrealistic assumptions lead to optimal 
cutoffs that are considerably more stringent than is expected in the clinic. Part of this is 
because the actual prevalence of unacceptable plans is fortunately much less than the 
unweighted prevalence of 50%. Different cutoffs may be obtained by varying these 
weighting factors. When the cost was manipulated to achieve an optimal threshold of 3% for 
the ion chamber, this resulted in a cost of passing an unacceptable plan as 0.06 times (about 
1/16) the cost of failing a truly acceptable plan. That is, in order to calculate an optimal 
cutoff of 3% for an ion chamber, this dosimeter must be heavily weighted to preferentially 
pass both acceptable and unacceptable plans. This is in surprisingly direct opposition to 
reasonable clinical goals, which would be to err on the side of caution and preferentially fail 
plans to ensure no unacceptable plans are passed. This same weighting (0.06) was used for 
all other devices to create the percent of pixels passing criteria that was equivalent (in 
weighting) to the 3% criteria for the ion chamber (Table 5). The weighted thresholds show 
lower percent of pixels passing values than the unweighted thresholds. The amount that the 
thresholds decreased varied among devices. Some showed substantial lowering, whereas 
others changed only modestly. This is consistent with the fairly large error bars on these 
thresholds. 
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4.4 DISCUSSION 
This research showed that not all of the IMRT QA systems analyzed in this work can 
equally differentiate between acceptable and unacceptable patient plans. This could be a 
reflection of the differing measurement geometries, resolution of the measurements, and 
implementations of the data analyses. In fact, none of the devices sorted the plans in the 
exact same manner as the gold standard. Despite this, the various QA systems were able to 
be divided into two groups with significantly different abilities to accurately classify plans. 
The better performers included the cc04 ion chamber, AP composite MapCheck, 
radiographic film, and ArcCheck, whereas the field-by-field and rotational MapCheck 
performed poorer than this group. 
The AUC averages in the better-performing group ranged from 0.815 to 0.937. A 
guideline for assigning a qualitative assessment to the AUC values states that 0.5<AUC≤0.7 
is “less accurate,” 0.7<AUC≤0.9 is “moderately accurate,” and 0.9<AUC<1 is “highly 
accurate” (Greiner 2000). The better-performing group is therefore moderately to highly 
accurate, whereas the poorer-performing group (ranging from 0.654 to 0.661) would qualify 
as “less accurate.” The single ion chamber showed the highest individual AUC but still 
showed discrepancies from the gold standard due to differences in the measurement 
geometry (single versus multiple measurement points). If the local dose around the single 
ion chamber matches the TPS plan yet deviates in other locations, even the most stringent 
passing criteria might not be able to label the plan as failing. Task Group 120 (Low 2011) 
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discussed how an ideal IMRT dosimeter would be able to truly sample the plan three 
dimensionally; however, such dosimeters have not yet been proven clinically viable. 
Some insight is also available on the less well performing QA techniques. The field-
by-field MapCheck is particularly interesting because it showed such different abilities to 
correctly sort plans compared with the composite MapCheck, despite being derived from the 
same measurement data. The differences in their ability to classify plans stem entirely from 
the method of analysis. When AP-delivered beams were analyzed field-by-field on the diode 
array, most fields scored well on a gamma analysis for both failing and passing plans. 
However, when summed into a composite plane, the small errors compound, leading to a 
more sensitive test. Publications by Nelms (Nelms 2011) and Kruse (Kruse 2010) have 
demonstrated some of the shortcomings of field-by-field dosimetry, notably an inability to 
distinguish between clinically acceptable and unacceptable plans on the basis of percent of 
pixels passing. Nelms offers the explanation that hot and cold spots may appear per field 
without deviating enough to be detected using a gamma analysis; however, when summed 
together these deviations may lead to critical dose errors. Despite these results, a survey 
(Nelms 2007) showed that 64.1% of clinics use AP field-by-field measurements when 
performing MapCheck-based IMRT QA, whereas 32.8% use AP composite methods most of 
the time. Therefore, the question of field-by-field sensitivity is relevant to today’s QA 
practices. Composite diode array dosimetry can also be performed with the original 
rotational gantry angles, as was done in this study with the MapPhan phantom. However, 
due to the directional dependence of diodes, such an array will perform better when the 
beam is perpendicular to array surface (Low 2011). The manufacturer of the diode array 
cautions that non-normal incidence can lead to errors due to a corruption of 2D information 
78 
 
 
 
(the array appears 1D to the beams eye view) and the air cavities perturbing the fluence 
(SunNuclear 2007). This issue of directional dependence is a possible explanation for the 
relatively poorer performance of the MapCheck when all beams were delivered at their 
original gantry angles. 
Table 5 shows the optimal thresholds for each device and analysis technique 
examined in this study. These values establish thresholds to be used for IMRT QA that are 
founded on the fact that in the clinic, a 3% dose difference threshold is often used for ion 
chamber–based IMRT plan verification (Ezzell 2003). However, their clinical 
appropriateness can be questioned because this weighting indicates that the cost of 
misclassifying an unacceptable plan as acceptable is 1/16 (0.06 times) that of misclassifying 
an acceptable plan as unacceptable. While this seems like a counterintuitive weighting, the 
3% ion chamber threshold was not devised with this cost weighting in mind. This seems to 
suggest a priority of efficiency in the clinic. Use of this weighting for the planar dosimeters 
revealed thresholds that are generally consistent with clinical experience. At a 3%/3mm 
criteria, 90% of pixels passing was often within the confidence interval of the optimal 
threshold. Some QA methods (such as the ArcCheck at 3%/3mm) showed a weighted 
threshold that was well below 90% of pixels passing. If a clinic used 90% as its threshold, 
that could be interpreted as more preferentially weighting failing an unacceptable plan. This 
is clinically reasonable, and therefore a clinical threshold above the weighted value (or 
below in the case of dose difference for the ion chamber) in Table 5 is likely a clinically 
sound decision, whereas a threshold below (or above for ion chamber dose difference) the 
weighted value is more representative of a liberal cutoff that excessively passes plans, 
including unacceptable ones.  
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Future work may be able to expand upon this research by more precisely determining 
AUC and optimal cutoffs from an expanded set of patient plans with an even greater variety 
of treatment sites. More patient plan measurements may also lead to tighter confidence 
intervals. Compared with the wide range of devices and analysis techniques used by the 
physics community, this work has only measured a small subset of IMRT QA methods. 
However, the techniques described above could be used to study other methods and 
determine a clinically relevant cutoff threshold for any particular IMRT QA dosimeter and 
analysis technique. This could be done to meet the sensitivity, specificity, and financial cost 
needs of the clinic. Importantly, the results of the IMRT QA analysis act as a guideline for 
detecting issues with an IMRT plan; it is up to the scrutiny of the clinical team to apply good 
judgment in determining the acceptability of a plan before treatment. 
 
4.5 CONCLUSION 
Several commercial patient-specific IMRT QA dosimeters and methods were 
investigated for their ability to discriminate between acceptable and unacceptable plans on a 
set of clinical patient plans. An ROC analysis was applied to track the performance of the 
various methods as a function of the cut-off values (%dose difference for point 
measurements, % pixels passing for planar measurements). ROC analysis was also used to 
determine the optimal cut-off values for the various methods being investigated, including 
when weighted for different costs for falsely failing an acceptable plan versus falsely 
passing an unacceptable plan. 
To compare the methods, the areas under the ROC curve were calculated, revealing 
that different devices performed significantly poorer or better than others. When averaging 
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all analysis techniques for each QA method, the ion chamber, AP composite MapCheck, 
ArcCheck, and radiographic film performed well, whereas the AP field-by-field and 
rotationally delivered MapCheck performed poorer than this group. 
The classification abilities for each device at 2%/2mm, 3%/3mm, and 5%/3mm 
gamma criteria did not produce statistically different results. That is, a similar level of 
accuracy in sorting acceptable and unacceptable plans could be expected at different criteria. 
Naturally, at these different criteria, a different percent of pixels passing would be 
necessary. For example, at the more liberal 5%/3mm, a very high cutoff would be needed to 
have an adequate sensitivity.  
Without weighting, the optimal cutoff for the ion chamber was a 1.6% dose 
difference. Although this is a stringent QA threshold, it is calculated with the assumption 
that half the IMRT plans undergoing QA are failing (without weighting). The QA devices 
using a gamma analysis show wider confidence intervals for the 2%/2mm criteria, reflecting 
the nature of the data bunching up against the 100% of pixels passing value with the looser 
criteria. With a failing plan prevalence of 0.03 and a clinically reasonable cost weighting 
that placed the ion chamber at an optimal threshold of 3%, the optimal thresholds of the 
devices migrated to lower sensitivities, indicating that the weighting necessary for a 3% ion 
chamber cutoff shows a priority towards lowering the incidence of falsely labeling a plan as 
failing. These values are available to use, but with a cost-benefit analysis balancing the cost 
of falsely detecting an unacceptable or acceptable plan, an optimal cutoff could be tailored 
for an individual clinic’s needs. 
This work shows that depending on the QA system being used, different 
considerations need to be made. The same cutoff criteria do not yield the same classification 
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abilities across all devices. Also, this work has shown that QA systems have different 
abilities to accurately sort acceptable and unacceptable plans. This information can help 
guide clinics to making more informed decisions when considering how and which patient-
specific IMRT QA devices to use in the detection of plan errors. 
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II. Chapter 5 
OVERALL DISCUSSION AND CONCLUSIONS 
 The original goal of this body of research was to compare the sensitivities among 
several clinical IMRT QA dosimeters, as detailed in the hypothesis.  However, in 
approaching that narrow problem it was found that many more extensive questions could be 
answered with this data, notably how well a dosimeter system could classify acceptable and 
unacceptable plans, recommendations for QA cutoff values, the effect of choice of analysis 
on the QA performance, the reproducibility in patient-specific IMRT QA measurements, and 
the relationship between dose gradient across the ion chamber and the reproducibility of an 
ion chamber measurement.  All of these topics address current clinical practices and 
assumptions made in patient-specific IMRT QA, and it is the hope of this author that the 
body of research outlined in this thesis will provide guidance in clinical decisions, and give 
the researcher the analysis tools to pursue further study in this area of research. 
 The hypothesis that none of the QA devices investigated would have sensitivities 
over 0.90 at 3%/3mm and 90% of pixels passing for planar, and 3% dose difference for 
point dosimeters, was trivially proven true in the course of this research.  In fact, at these 
conventional passing criteria, the devices with the highest sensitivity were the film and 
ArcCheck, tied at 0.60.  This means that only 60% of the unacceptable plans (as determined 
by the gold standard) were detected as failing.  Although the hypothesis focused on the 
sensitivities of a dosimeter, it is also important to consider the ability to correctly label 
acceptable plans as passing (specificity); otherwise the dosimeter may give an excessive 
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number of false alarms.  The ROC analysis allowed this research to balance investigating 
sensitivity, specificity, and appropriate cutoff values for each dosimeter system under the 
varying selections of analysis software and criteria.  This has considerably expanded the 
scope of the clinical relevancy of this project. 
 When comparing the performance of different dosimetric systems, the 
reproducibility of such measurements is a natural question that arises.  While the bulk of this 
was answered in Chapter 3 while discussing reproducibility, the performance comparisons 
study reveals another facet of this question.  When faced with an ion chamber-based plan 
failure in IMRT QA, a strategy is to take the measurement again at another point.  While 
there is a chance that the original point measurement failed due to poor measurement 
geometry, Kruse’s research points out that dosimetric accuracy is not necessarily the same 
throughout a patient plan (Kruse 2010).  The multiple ion chamber phantom measurements 
seem to verify this assertion.  It took a three-dimensional sampling of the patient plans 
investigated in this research, and showed how variation in dose difference between 
measurement and calculation can occur throughout an IMRT plan.  Therefore, when 
retaking a measurement, the results of the IMRT QA may vary due to detector 
reproducibility and due to a choice of different measurement location. 
 Finally, the paramount question is, how do these results affect the treatment that the 
patient ultimately receives?  A study in the literature (Dische 1993) has shown how a ±5% 
dose difference can lead to loss in tumor control or heighten the risk to normal tissue.  Dong 
et al found that of 751 IMRT plans investigated, 3.1% showed a dose difference of greater 
than 3.5%.  Although this shows a low incidence, it also shows that the incidence of 
unacceptable plans is nonzero.  IMRT involves a complex chain of steps to get from 
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simulation and planning to delivery.  Patient-specific QA offers a safeguard between 
potential mistakes along that chain, and the dosimetric accuracy of the patient’s IMRT 
treatment.  It provides a preemptive, quantitative test to give guidance on the acceptability of 
an IMRT plan.  Therefore, it is important to understand the abilities and limitations of the 
quantitative test results of dosimeters used in QA, both in terms of accurately sorting 
acceptable and unacceptable plans and in their reproducibility.  Studies have been done to 
evaluate the sensitivity and reproducibility of detector systems, but this work focuses on the 
end result seen in the clinic and used for guidance: notably the percent of pixels passing for 
planar measurements and dose difference for point measurements.  While it is ultimately up 
to the clinician’s knowledge and expertise on whether the plan is acceptable, these QA tests 
provide a valuable metric in the aid of that decision-making. 
Future Work 
 The methods described in this thesis could provide a framework for aiding in the 
optimization of a patient-specific IMRT QA program.  The ROC analysis gives researchers 
the ability to assess their dosimeters’ abilities, and with a clinic-specific cost-benefit 
analysis, arrive at a quantitatively derived cutoff value.  An expansion on this work may be 
to produce a training set of clinical plans that have already been sorted with a gold standard, 
and send them out to centers that may wish to determine the performance of any dosimetric 
system that may not have been addressed in this work. 
 While the error bars for the AUC’s were generated using bootstrapping, this analysis 
could be expanded by introducing replicates for the generation of ROC curves.  Also, the 
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reproducibility study only had three repeat measurements and looked at six patient plans.  
Additional repeated measurements and patient plans may expand that investigation. 
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IV. APPENDIX I 
RECEIVER OPERATOR CHARACTERISTIC CURVE ANALYSIS 
 In order to grant the reader a more in-depth explanation of a core methodology 
explored in this thesis, this appendix endeavors to better explain the nuances and mechanics 
of the receiver operator characteristic (ROC) curve.  The ROC curve is a useful depiction of 
the performance capabilities of a diagnostic test with dichotomous results, that is, either a 
positive or negative outcome.  The appropriate test will have many continuous 
measurements requiring a cutoff value to separate the binary results.  The ROC curve 
incorporates the concepts of sensitivity and specificity, concatenating these concepts by 
plotting their changing values as the cutoff is varied from liberal to stringent.  Traditionally, 
the vertical axis is sensitivity, while the horizontal axis is 1 – specificity, such that the ideal 
curve reaches to the upper left corner.  An example ROC curve was shown in Figure 13. 
Sensitivity is the ability to label a truly positive result as positive, while specificity is 
the ability to label a truly negative result as negative.  Using the notation of true positive 
(TP), true negative (TN), false positive (FP), and false negative (FN), the equations for these 
concepts are shown below. 
             
  
     
     Equation 7 
             
  
     
    Equation 8 
93 
 
 
 
This introduces the need to establish the “truth” by which the test under investigation will be 
compared.  A gold standard is used to determine the veracious classification of each 
measurement.  A pool of several measurements is needed to establish reliable values of 
sensitivity and specificity for each cutoff.  As discussed in the body of this thesis, this work 
measured 24 patient plans (the pool of measurements), on six different IMRT QA dosimeter 
techniques (the tests being investigated), and compared the classification of those 24 plans 
by each dosimeter to the results given by the multiple ion chamber phantom measurements 
(gold standard).  For all plans except the cc04 ion chamber, the gamma index was used, 
giving a cutoff value in terms of percent of pixels passing.  The cc04 ion chamber used 
percent difference between the plan and the measurement as its cutoff.   
 Another way to think of ROC analysis is as a binormal distribution of positive and 
negative measurements and their respective probability density functions (Figure 18).  The 
more overlapped the two distributions, the more difficult it is to accurately sort the positive 
and negative results.  Below is an example of such a distribution.  The solid normal curve is 
the negative test probability density function, while the dotted normal curve is the positive 
one.  The vertical line represents a chosen cutoff, above which a measurement is classified 
as positive.  However, we can see that the upper tail of the negative normal curve will be 
counted among the positive measurements with this cutoff.  This serves to illustrate the 
inherent tradeoff between sensitivity and specificity.  One can make the cutoff more 
stringent to catch more positive measurements, but at the cost of falsely including some 
negative measurements. 
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Figure 18 Binormal curve of probability densities for positive and negative 
observations 
An ROC curve provides a convenient way to graphically display this tradeoff, 
allowing the viewer to decide what level of sensitivity or specificity they desire out of their 
diagnostic test, and then pick the corresponding cutoff value at that point.  However, if the 
user does not know a priori what sensitivity and specificity they desire, but instead wishes to 
maximize the overall performance of the test, there are many choices available to pick the 
optimal cutoff value.  Two common methods are to find the point along the ROC curve 
closest to the top left corner (the (0,1) method, Equation 9), or find the point farthest from 
the line of random guessing (Youden Index, Equation 10).  This random guess line is the 
straight diagonal from the bottom left corner to the top right corner.  In the equations 
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defining the optimal cutoffs below, c is the cutoff, q(c) is the sensitivity as a function of 
cutoff, p(c) is the specificity as a function of cutoff. 
Equation 9 
             
 
          
 
                 
 
          
 
  
Equation 10 
                                                 
However, in practice the additional parameters of cost and prevalence play a role in 
the selection of an optimal cutoff value.  According to a seminal paper on ROC analysis 
(Metz 1978), if the disease prevalence is low, then the false positive fraction must also be 
kept low, meaning an ideal point would be pushed more towards the lower left of the ROC 
curve.  This is balanced by looking at the consequences, or cost, of false negatives (missing 
a failing plan) and false positives (missing a passing plan).  If the costs of a false negative 
outweigh a false positive, then the ideal cutoff moves towards the upper right of the ROC 
curve, and vice versa.  Perkins and Schisterman (2006) (Perkins 2006) showed that of the 
two methods of finding an ideal cutoff, the Youden index displays a more robust and 
reliable response when prevalence and cost are taken into account.  Equation 11 shows how 
the Youden optimal cutoff is determined when cost and prevalence are included. 
Equation 11 
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 Empirical ROC curves can appear jagged and have a staircase pattern due to the few 
measurements made due to limitations in time and resources.  Using a binormal fit has been 
shown to be a robust method of smoothing an ROC curve (Hanley 1988).  This can be used 
to give the user a snapshot of how the curve might appear if more data were available.  The 
data is assumed to have a distribution like the one shown in Figure 18.  An example of 
smoothing using a binormal fit is shown in Figure 19. 
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Figure 19 The empirical and smoothed ROC curves for the cc04 ion chamber 
The jagged nature of the empirical curves can also affect the choice in optimal cutoff, 
especially if the cost and prevalence are such that the point would occur in a straight part of 
the lower left or upper right ROC curve.  When faced with this situation, the optimization 
algorithm may never reach a certain point on the curve.  To address this issue, the threshold 
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optimization estimation can be considered not by the geometries of the ROC plot, but 
through a cost minimization function.  This function has been discussed in the literature 
(Skaltsa 2010).  When only the empirical version of this method is considered, no 
assumptions need to be made about the underlying distributions of the data; therefore in this 
body of work (Chapter 4), the empirical cost minimization method was used.  Optimal 
thresholds are estimated by setting the ratio of probability distribution functions for positive 
and negative plans equal to the negative odds ratio times the cost ratio: 
  
Equation 12 
                  
                   
   
                              
                            
  
 
                                                  
  
Empirically, this means that the cutoffs are varied until the value of the ratio of sensitivity to 
specificity equals the right hand side of Equation 12.  The proof for this is shown in the 
paper by Skaltsa et al (Skaltsa 2010). 
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V. APPENDIX II  
BOOTSTRAPPING 
 Sometimes in research, due to limitations in resources, multiple replicates are not 
feasible in the acquisition of the data.  However, it is important to be able to gauge the 
uncertainty in one’s measurements.  In order to accomplish this, a technique known as 
bootstrapping has been established to create confidence intervals on datasets with limited 
replicates.  Bootstrapping is a well accepted technique which uses resampling of the data to 
estimate confidence intervals (Carpenter 2000).  In order to estimate a given population 
parameter, a measurement is made on a random sample taken from that population.  Each 
time a re-measurement is made, it is another random sample from the population.  
Therefore, one can simulate multiple random samples through randomly re-sampling from 
actual measurements.  These resampled data can be used to calculate multiple values of a 
population parameter.  Bootstrapping thus yields a range of values from which the 95
th
 
percentile can be selected and applied to the parameter calculated from the original 
measurement (Carpenter 2000).  This technique was applied in this research to calculated 
confidence intervals for the area under the curves and the optimal cutoff values in Chapter 4. 
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VI. APPENDIX III  
MULTIPLE ION CHAMBER PHANTOM PASS/FAIL CRITERIA 
Because the multiple ion chamber phantom (MIC) was designed in-house, a metric to 
determine if the results of its measurement were passing or failing had to be determined.  A 
single value was distilled from incorporating all ion chamber measurements (see Chapter 4).  
In order to determine the cut off value of this MIC metric that would classify a plan as 
passing or failing, a study on the robustness of different metrics was conducted.  This 
robustness was gauged by the metric’s ability to consistently sort all 24 patient plans across 
minimum dose threshold cutoffs and percent standard deviations in the dose across the ion 
chamber volume.  To evaluate this, a program was written which iterated through the dose 
thresholds of 35%, 50%, and 65%, standard deviations of 1%, 2%, and 3%, and an MIC 
metric of 0.01 – 0.6.  It was found that the MIC metrics 0.27 – 0.35 were all the most robust, 
and all sorted the plans the same way.  Therefore, 0.30 was selected in order to be confident 
that the sorting would not be changed by slight changes in dose level or gradient. 
An example of how the MIC uses the 10 ion chamber measurements to sort a plan as 
acceptable or unacceptable is shown on the next page
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VII. APPENDIX IV 
ADDITIONAL FIGURES 
ROC curves created for each dosimeter system (cutoffs are both numerically printed on the 
curves, and color coded) 
 
103 
 
 
 
 
104 
 
 
 
 
105 
 
 
 
 
106 
 
 
 
 
107 
 
 
 
 
108 
 
 
 
 
109 
 
 
 
 
110 
 
 
 
 
111 
 
 
 
 
112 
 
 
 
 
113 
 
 
 
 
114 
 
 
 
 
115 
 
 
 
 
116 
 
 
 
 
117 
 
 
 
 
118 
 
 
 
 
119 
 
 
 
 
120 
 
 
 
 
121 
 
 
 
 
122 
 
 
 
 
123 
 
 
 
 
124 
 
 
 
 
125 
 
 
 
 
126 
 
 
 
 
 
 
 
 
127 
 
 
 
 
The empirical ROC curves (red) are plotted with their smoothed counterparts (green, 
binormal smoothing).  The Area Under the Curve for each empirical curve is printed on the 
plot. 
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In order to assess whether a particular dosimetric system’s AUC was significantly different 
from another’s, a D-test was performed for each pair of AUC’s.  The test statistic for the D 
test is the difference in AUC’s divided by the standard deviation of the differences between 
each bootstrapped AUC.  This yielded the following table of p-values. From this table, it 
was found that there was not a statistically significant difference between any pair of gamma 
criteria for a given device (i.e. the AUC for film at 2%/2mm was not different from film at 
3%/3mm, or 5%/3mm).  However, these p-values are for pair-wise comparisons.  With so 
many individual comparisons, there is a non-trivial probability that you will achieve 
significance in a pair by chance.  After adjustment of p-values for this effect, it was found 
that the AUC results between Doselab and SNC Patient were not significantly different.  The 
findings from this table are discussed on page 65. 
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A plot of the standard deviation in the dose across the ion chamber vs the reproducibility in 
the measurement.  Each data point has been color-coded based on which ion chamber was 
used for its measurement 
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A plot of the different regression lines that resulted from a 0, 1, and 2mm ROI expansion 
around the ion chamber 
 
  
163 
 
 
 
 
The following four plots are the same as in Figure 11, except a 1, 2, 3, and 5mm expansion 
around the ion chamber ROI was used to calculate the standard deviation in the dose across 
the ion chamber
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These plots show the results of the autocorrelation of residuals performed in the 
reproducibility when trying to see if the choice in ion chamber or patient plan would 
influence the regression.   
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Results of ANOVA and Tukey HSD for grouping devices by their CV 
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The raw data of each IMRT QA measurement made on each patient 
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